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Abstract
Background: ABCA1 is an ubiquitous plasma membrane transporter that
promotes the eﬄux of cholesterol and phospholipids from the cell membrane
to an extracellular acceptor, known as apolipoprotein A-I (apoAI), the main
protein constituent of plasma high density lipoprotein (HDL). ABCA1 me-
diated cholesterol/phospholipids eﬄux leads to the extracellular formation
of HDL. Loss of function mutations of both ABCA1 alleles is the cause
of Tangier Disease (TD), a recessive disorder characterized by extremely
low levels of plasma HDL, increased risk of cardiovascular disease (CAD)
and other clinical manifestations. Heterozygous mutations of ABCA1 gene
cause Familial HDL Deficiency (FHD), characterized by half normal level
of HDL-C and increased CAD risk. Familial Hypercholesterolemia (FH) is
a monogenic disorder due to mutations of LDLR gene. In addition to the
striking elevation of plasma LDL, FH patients (especially homozygotes) have
greatly reduced plasma HDL levels, suggesting that they may have a defect
in ABCA1-mediated cholesterol eﬄux pathway. Aim: Specific aims of this
work were: i) the identification and functional characterization of several
new ABCA1 mutations found in TD and FHD; ii) the study of ABCA1
regulation in fibroblasts derived from FH patients. Methods: ABCA1 gene
was analyzed in 27 subjects with familial low HDL-C levels, by DHPLC and
direct sequencing. Among the novel 22 mutations identified, 3 splice site mu-
tations, 6 missense mutations and 1 frameshift mutation were investigated.
The effect of splice site mutations was investigated ex-vivo, using patients’
fibroblasts or blood mononuclear cells, or in vitro by looking at transcripts
generated by the expression of a mutant ABCA1 minigene in a heterologous
cell system. ABCA1 protein expression was studied in eight FH derived fi-
xi
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broblast cell lines under different conditions: basal culture conditions, stim-
ulation with free cholesterol (FC), 22-hydroxycholesterol/9cis-Retinoic Acid
(22OH/9cRA), or the LXR agonist T0901317. Cholesterol eﬄux to ApoA-I
was also measured in these fibroblasts. Main results: 22 novel ABCA1 mu-
tations were reported. The effect of 3 splice site mutations (c.814-14InsA,
c.2961-2A>C, c.4773+1G>A) was investigated with an ex-vivo or with a
minigene approach. The c.814-14InsA resulted to be non-pathogenetic, the
c.2961-2A>C resulted in the generation of three abnormally spliced mRNA
species, the c.4773+1G>A caused the formation of an ABCA1 protein con-
taining an in-frame deletion, which was poorly synthesized by cells. Five ad-
ditional fibroblast cell lines derived from TD or FHD patients were studied
in terms of ABCA1 protein expression and function. Fibroblasts carrier of
R587W, A1046D, D1099Y, H1600R/M586Fs.629X, R130K/N1800H showed
a null ABCA1-mediated cholesterol eﬄux. ABCA1 protein expression was
studied in eight FH fibroblasts under different stimuli. Under basal culture
conditions ABCA1 expression resulted lower in FH cells with respect to con-
trol cells. This reduction was observed also after stimulation of cells with
a load of FC or with 22OH/9cRA, known to stimulate ABCA1 expression
via the transcription factor LXR. Treatment of cells with a non-steroidal
LXR agonist (T0901317) was able to restore an ABCA1 expression similar
to that of control fibroblasts. Also ABCA1-mediated cholesterol eﬄux in
FH fibroblasts was lower than in control fibroblasts. Conclusions: Among
27 individuals with low HDL-C, 22 novel mutations in ABCA1 gene were
identified. Three splice site, 6 missense and 1 frameshift mutation were
functionally characterized in TD/FHD derived cells, allowing us to gain in-
sight on genotype-phenotype correlations. Furthermore we demonstrated a
defect in ABCA1 protein expression and function in FH, which may be partly
responsible for the low plasma HDL-C levels exhibited by FH patients.
Chapter 1
INTRODUCTION
1.1 ABCA1 protein
1.1.1 ABC proteins family
ATP-binding cassette (ABC) transporters constitute one of the largest known
protein superfamilies. These evolutionary highly conserved multispan trans-
membrane molecules use the energy of ATP hydrolysis to translocate a broad
spectrum of molecules across the cell membrane. Substrates that are trans-
ported by ABC molecules include lipids, peptides, amino acids, carbohy-
drates, vitamins, ions, glucuronide and glutathione conjugates and xenobi-
otics. In eukaryotes, ABC transporters are located in the plasma membrane,
in the membranes of intracellular compartments such as the Golgi, endo-
somes, multivesicular bodies, endoplasmic reticulum, peroxisomes and in
mitochondria. To date, 59 members of the human family of ABC trans-
porters have been identified which, based on their structural relatedness, are
subdivided into 7 families, designated ABC A–G [1,2].
Among these we cite:
• Subfamily ABCA, including 12 transporters, which is distinguished
from others for being expressed only by multicellular organisms. In this
subfamily, transmembrane domains and ATP binding domains consti-
tute a single polypeptide.
• Subfamily ABCB, including transporters involved in multidrug resis-
1
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tance.
• Subfamily ABCC, including proteins which mediate ions transport,
toxins elimination and signal transmission. The most famous is CFTR
(Cystic Fibrosis Transport Regulator), which mediate Cl2 export: func-
tional defects in this transporter are responsible of Cystic Fibrosis.
Functional ABC transporters show a common global organization. So-called
“full-size ABC transporters” are typically composed of two tandemly linked
functional units while “half-size transporters” are usually composed by a sin-
gle unit; each ABC unit (200-250 aa) contains 2 short, highly-conserved pep-
tide motives directly involved in ATP binding (called Walker A and Walker
B) and an “ABC signature” localized between them.
Being membrane transporters, ABC proteins contain one or more trans-
membrane domains, tipically constituted by 6 helices, which can either be
part of a single polypeptide (full-transporters) or be involved in a multi-
protein complex bound to the membrane, so that they can form homo- or
heterodimers, which consist of two half-size transporters that are encoded
by distinct genes.
It is thus conceivable that full-size ABC transporters, as large compo-
nents of membrane associated multiunit complexes, are not necessarily re-
stricted to serve one defined function but are likely involved in a spectrum
of biologic activities depending on the specific assembly of the functional
complex and the biologic activities of their interaction partners [3].
1.1.2 ABCA1 protein structure
ABCA1 (formerly known as ABC1) is the prototypic member of ABCA sub-
family and was initially identified by Luciani et al. [4] in mouse in 1994; 5
years later it was found to be responsible of two human genetic diseases [5],
familial high-density lipoprotein (HDL)-deficiency (FHD) and Tangier dis-
ease (TD), which identified ABCA1 as a major regulator of HDL metabolism
[6-8].
ABCA1 is an integral membrane full-size transporter formed by two mir-
ror halves each one containing 6 transmembrane domains, one large, highly-
glycosylated, extracellular loop and one Nucleotide Binding Domain (NBD)
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composed by two conserved peptide motifs known as Walker A and B (thus it
binds two ATP molecules). Both amino and carboxi-terminals are intracito-
plasmatic [9]. The two large extracellular loops are linked by a disulfide
bond.
It is a 2261-amino acid polypeptide with a molecular weight of 220 kDa
[10,11].
Figure 1.1: ABCA1 protein structure.
ABCA1 is a ubiquitous protein and promotes the unidirectional active
transport of two major components of the plasma membrane, cholesterol and
phospholipids, to an extracellular acceptor represented by some apolipopro-
teins (the main one is apolipoprotein A-I, apoA-I) [12,13]. This ABCA1-
mediated eﬄux is one of the first steps involved in the Reverse Cholesterol
Transport (RCT), a process by which cholesterol is eliminated from periph-
eral cells and transferred to the liver via the plasma compartment.
A fraction of ABCA1 is located in internal endocytic compartments where
it may facilitate cholesterol eﬄux from early/late endosomes and lysosome
[14]; it is also likely that ABCA1 influences vesicles trafficking from Golgi
apparatus, maybe through its phospholipid-transferase activity [15].
Recent studies, however, suggested that ABCA1 transports cholesterol
to apolipoproteins exclusively at the cell surface [16-18] thus different mech-
anisms of action are still proposed and have to be considered.
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1.1.3 Cell cholesterol eﬄux
The intracellular cholesterol content is the result of three different metabolic
processes: endogenous synthesis, LDL-mediated internalization and elimina-
tion (see 1.5.2). The combination of these mechanisms is highly dynamic to
meet cellular requirements and it is important that the equilibrium is main-
tained to avoid a damaging over-accumulation of free, unesterified cholesterol
(FC). Even a too large accumulation of esterified cholesterol (EC) is respon-
sible of cellular damage as it happens in macrophages. This is the reason
why a redundancy and complementarity of mechanisms exist to manage cell
cholesterol eﬄux.
Four are the main processes involved:
i) the first one is a bidirectional passive diffusion mechanism, where free-
cholesterol molecules spontaneously dissociate from the plasma membrane,
diffuse through the aqueous phase and are incorporated in high density
lipoprotein (HDL) particles by collision [19].
ii) The second mechanism is a bidirectional transport mediated by scav-
enger receptor class B type 1 (SR-B1): on one side SR-B1 is the receptor for
HDL, mediating the transport of cholesterol and cholesteryl esters from HDL
particles [20,21]; on the other side it favours the excretion of cholesterol via a
facilitate passive transport. It is primarily expressed in liver and nonplacen-
tal steroidogenic tissues where SR-B1 directly interacts with HDL particles,
releasing cholesterol and phospholipids localized on the plasma membrane
[22-24].
iii) The third mechanism is an ABCA1-mediated unidirectional trans-
port: ABCA1 is involved in ATP-dependent cholesterol eﬄux and its main
acceptor is lipid poor apoA-I, the main peptide component of HDL particles
[25].
iv) A fourth, recently identified, mechanism proposes the involvement of
the ABC transporter G1 (ABCG1), widely expressed in human tissues, in
promoting the eﬄux of cholesterol to mature HDLs. This ABCG1-mediated
eﬄux has not been completely characterized yet but it probably contributes
and complements ABCA1 transport.
It is hard to define which of these four mechanisms is the most important
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due to the fact that they have different roles in different types of cells. The
most efficient seems to be the ABCA1-mediated cholesterol eﬄux: phospho-
lipids and unesterified cholesterol are transferred to a monomolecular, pre-β-
migrating, lipid-poor or lipid-free form of apoA-I. This mononuclear form of
apoA-I is quite distinct from the pre-β-migrating discoidal HDL which con-
tain 2 or 3 molecules of apoA-I per particle and which are present as minor
components of the HDL fraction in human plasma [26,27]. The cholesterol-
phospholipid complex transferred to apoA-I forms or increases its lipid con-
tent, creating nascent, pre-β-HDL which increase their lipid content, during
their movement in lymphatic and blood circulation. Free cholesterol taken
up by HDL is then esterified by lecithin:cholesterol acyltransferase (LCAT)
and hydrophobic cholesteryl esters are retained into the core of HDL so that
new cholesterol molecules can be translocated on the HDL surface. The en-
richment of cholesterol and localization of cholesteryl esters in the core of
the particles lead to transformation of discoidal pre-β-HDL into spherical
mature HDL.
If ABCA1-mediated cholesterol and phospholipid transport doesn’t oc-
cur, then apoA-I is not enriched in lipids and is rapidly catabolised by the
kidney. The total amount of HDL in the plasma therefore shows a large
decrease.
1.1.4 Reverse Cholesterol Transport
Reverse Cholesterol Transport is a process where exceeding cholesterol is
removed from peripheral, extra-hepatic tissues and transported to the liver
for reuse in enterohepatic cycle where it can be converted in biliary acids or
eliminated via biliary excretion [28].
HDL and apoA-I ability to promote Reverse Cholesterol Transport is
believed to be one of the main atheroprotective mechanisms.
Atherosclerosis is a progressive disease characterized by the accumulation
of cholesterol in the arterial walls. Increased levels of low-density lipopro-
tein cholesterol (LDL) are causally related to atherosclerosis, supported by
substantial evidence from large-scale intervention trials, from animal studies,
and from genetic studies of families and of the general population. LDL par-
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Figure 1.2: Reverse Cholesterol Transport.
ticles in plasma enter the arterial wall where they are oxidized. In response to
oxidized lipids, arterial-wall cells secrete proteins that attract monocytes into
the intima and lead to their locally differentiation into cholesterol-engorged
macrophages, the so-called foam cells which continuously accumulate lipids.
These foam cells constitute the initial lesions that subsequently develop into
more advanced atherosclerotic plaques, characterized by the accumulation of
lipid-rich necrotic debris and smooth muscle cells. Plaque rupture and to-
tal occlusion due to thrombus formation result in clinical ischemic vascular
events.
In this process, the Reverse Cholesterol transport assures mobilization
of excess cellular cholesterol from arterial-wall macrophages preventing or
reducing foam cell formation [29].
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1.1.5 Mechanism of action of ABCA1 protein
Many different models have been proposed so far to explain ABCA1 mech-
anism of action.
The three main processes are the following:
• In a first model a direct interaction with a small regulatory pool of
apoA-I is required in order to transfer lipids outside the cell [30];
ABCA1 recognizes and interacts with a cluster of amphipathic helices
in the apolipoprotein structure. This interaction likely involves the first
and forth extracellular loop [31,32]. Formation of novel apolipoprotein
binding structures protruding from the cell surface results as an inter-
mediate step in the pathway by which apolipoproteins remove excess
cholesterol from cells [33]. In this model ABCA1 moves cholesterol and
phospholipids to the outer leaflet, but it isn’t known if this transfer is
either simultaneous or phospholipids are transferred before cholesterol
[34] or, in a third option, the translocation is simultaneous unless phos-
pholipid and cholesterol-rich domains are too distant so that the two
phases are dissociated.
• In the second model ABCA1 is able to reach and bind the plasma
membrane without necessarily interact with apoA-I. The two symmet-
rical ABCA1 transmembrane bundles come together to form a cham-
ber that scans the inner leaflet of the membrane for substrates, in-
corporates them into the chamber, and flips them to the outer leaflet
for extrusion from the cell. This involves a series of conformational
changes in the ABC protein that is driven by ATP hydrolysis in the
NBD domains. ABCA1 amino acid motifs in the chamber are likely
to bind phospholipids. Again, it is unknown whether inner leaflet
cholesterol is co-transported with these phospholipids or phospholipids
translocation alone increases the accessibility of cholesterol that flips
to the outer leaflet by other processes. The observation that ABCA1
can affect the cholesterol content of lipid rafts, which probably relies
on lateral diffusion of cholesterol along the membrane, supports the
idea that ABCA1 also translocates cholesterol [35]. When induced
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by cholesterol loading of cells, ABCA1 therefore constitutively gen-
erates cholesterol and phospholipid-rich membrane domains, even in
the absence of apolipoproteins [36] and these domains bend from the
plasma membrane to relieve the strain of the densely packed phos-
pholipids, generating curved and disordered lipid surfaces that favour
apolipoprotein interactions. During the first several minutes of ex-
posure to apolipoproteins, JAK2 is activated by autophosphorylation,
which in turn increases binding of apolipoproteins to ABCA1. This
binding facilitates the interaction of apoA-I with the protruding lipid
domains, promoting their solubilization and release from the cells.
• The third model involves retroendocytosis; the pioneering study of
Takahashi and Smith [37] showed that following internalization, apoA-
I is recycled back to the cell surface to be re-secreted. Other stud-
ies showed that apoA-I and ABCA1 are co-localized in endosomal
compartments, and that ABCA1 rapidly shuttles between intracellu-
lar compartments and the plasma membrane [38,39]. These results
support the idea that ABCA1-bound apoA-I is delivered from the
plasma membrane to early and late endosomal and/or lysosomal com-
partments, where it forms nascent lipoprotein particles that are sub-
sequently secreted from the cell. However, several groups examining
internalization and recycling of apoA-I concluded that the retroendo-
cytosis pathway does not contribute significantly to HDL formation
and that the majority of internalized apoA-I is directly transported to
late endosomes and lysosomes for degradation while only a small frac-
tion is re-secreted from cells and the majority of re-secreted apoA-I
seems to be degraded in the medium. These results suggest that the
mass of retroendocytosed apoA-I is not sufficient to account for HDL
produced by cholesterol eﬄux [17].
On the other side, it has been recently demonstrated that apoA-I exhibits
saturable association with the plasma membrane and intracellular compart-
ments (ICCs), that apoA-I induces ABCA1 endocytosis and co-localizes with
cell-surface derived ABCA1 on endosomal compartments; moreover apoA-
I dissociation from ICCs is 4-fold faster than from the plasma membrane
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and approximately 30% of endocytosed ABCA1 is recycled to the cell sur-
face giving a critical contribution to HDL formation under conditions where
cells have accumulated excess lipoprotein-derived cholesterol in endosomal
compartments [39,40].
In conclusion the mechanism of active cellular lipids ABCA1-mediated
eﬄux to apoA-I is not yet clear; it may involve 1) binding of apoA-I either
directly to ABCA1 or indirectly to a lipid site created by ABCA1 activity,
2) either simultaneous or sequential release of membrane phospholipid and
cholesterol to apoA-I, and 3) assembly of nascent HDL particles either at the
cell surface or at intracellular sites during the retroendocytosis of ABCA1
[30].
The precise mechanism of action of ABCA1 in promoting delivery of
cellular cholesterol and phospholipids to apoA-I remains to be determined.
Figure 1.3: Mechanism of action of ABCA1.The three mechanisms of action of
lipid-eﬄux ABCA1-mediated. Image adapted from [14].
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1.1.6 ABCA1 intracellular traffic
An important intracellular mechanism that seems to characterize ABCA1
pathway is the formation of multiple structures like dimers, tetramers and
oligomers.
In 2004 Denis et al. [41] demonstrated that the majority of ABCA1 exists
as a tetramer which binds apoA-I, that neither apoA-I nor lipid molecules af-
fect ABCA1 oligomerization and that apoA-I is associated with both dimeric
and tetrameric, but not monomeric forms of ABCA1. These findings sup-
port the concept that the homotetrameric ABCA1 complex constitutes the
minimum functional unit required for the biogenesis of HDL particles.
Trompier et al [42] further highlighted that ABCA1 is associated in
dimeric structures that undergo transition into higher order structures, i.e.
tetramers, during the ATP catalytic cycle. The assembly in homodimers
takes place in the endoplasmic reticulum, which is a rather common rule in
the assembly of multimolecular channel structures; the ABCA1 dimers are
oriented so that the C-terminal extremities of ABCA1 are in close proxim-
ity. Both a putative PDZ binding motif present at the C terminus and the
VFVNFA sequence located at positions 2210–2215 have been identified as po-
tential interaction sites; they may be required either to stabilize the dimeric
interaction or to introduce additional molecular partners in the complex.
These assemblies are transient in nature but can be trapped experimentally
by interfering with the ATP catalytic cycles, namely by stabilizing the ATP-
bound state; they are tetramers, rather than dimers, undergoing major con-
formational changes upon ATP binding. Resetting of the transporter in the
initial conformation takes place after eﬄuxes of membrane phospholipids.
As explained in 1.1.3, current evidences suggest that ABCA1-mediated
cholesterol eﬄux to apoA-I involves mobilization of cholesterol from plasma
membrane, endoplasmic reticulum, trans-Golgi network, late endocytic and
lysosomal compartments and cholesteryl ester droplets.
Neufeld et al [38] indeed demonstrated that ABCA1 resides on the surface
of both small, mobile vesicles as well as on large, relatively immobile perin-
uclear vesicles. The small, fast-moving ABCA1-containing vesicles are likely
to represent early endosomes, whereas the ABCA1-containing large, static,
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perinuclear vesicles are likely to represent late endocytic compartments (late
endosomes/lysosomes). The ABCA1-containing early endosomes undergo fu-
sion and fission events: they transiently interact with one another, with the
ABCA1-containing late endocytic vesicles, and with the cell surface. They
shuttle and tubulate while moving vectorially, consistent with directed move-
ment along cytoskeletal elements such as microtubules or actin filaments. In
addition to ABCA1, the membrane components that may be transferred
from the ABCA1 early endosomes to other cellular compartments may in-
clude substrate lipids for ABCA1 [43,44] and/or acceptor apolipoproteins
[38-40]. Cholesteryl Esters (CE) in LDL are hydrolyzed into unesterified
cholesterol in late endosomes and lysosomes and this cholesterol may serve
as a direct substrate pool for ABCA1-mediated cholesterol eﬄux to apoA-I,
suggesting that late endosome/lysosome cholesterol might represent a signif-
icant substrate pool for ABCA1 and HDL formation and this provides the
opportunity for the removal of excess endocytosed LDL-derived cholesterol
from the cell, prior to its potential distribution to other sites by NPC1.
Moreover, ABCA1 mobilizes endogenously synthesized cholesterol in the
Golgi apparatus to lipidate de-novo synthesized apoA-I [44]; it also depletes
cholesterol released from cytoplasmic cholesteryl ester droplets but since
there is no evidence of ABCA1 localization or association with cholesteryl
ester droplets, it is more likely that the unesterified cholesterol released from
cholesteryl ester droplets is transported rapidly to the plasma membrane,
via the Golgi apparatus, to become part of the ABCA1 substrate pool [45].
1.2 ABCA1 gene
The gene encoding ABCA1 transporter is located on the long arm of chro-
mosome 9 (9q31.1) [46], has a total length of 149 kb and includes 50 exons
and 49 introns. Exons dimensions vary between 35 bp (Ex 33) and 244 bp
(Ex 49). Introns dimensions are more variable, from a minimum length of
111 bp (IVS 38) to a maximum length of 24000 bp (IVS 1) [47].
Exon 1 encodes for part of the 5’ UnTraslated Region (5’UTR). Exon
2 encodes for the remaining part of 5’UTR, for the first methionine and
the subsequent 21 aa of ABCA1 amino-terminal region. The putative tran-
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Figure 1.4: ABCA1 intracellular traffic between early, late endosomes, lyso-
somes and the plasma membrane.
scription starting site is localized 315 bases upstream of the ATG in exon 2.
The open reading frame length is 6723 nucleotides. The nucleotide sequence
around the initial ATG in exon 2 is conformed to the Kozak consensus se-
quence (RNNATGG), with a purine in position -3 and a G in position +4
[47].
If translation starts at the ATG in exon 2, the protein obtained from
the corresponding mRNA contains 2261 aa [6,7,10,48]. The first 45 aa have
chemical and physical properties similar to those of the signal peptide of
many secreted proteins.
Another possible translation starting point is located in exon 4, where a
2201aa-long protein could originate. This ATG, however, is positioned in a
context not related to the Kozak consensus sequence; it is therefore unlikely
that this starting point is active [47].
With regard to the end of translation, the first polyadenylation site is
about 3000 bp downstream from the stop codon. Thus the 3’UTR of ABCA1
1.2. ABCA1 GENE 13
mRNA is quite long [11,46,47].
ABCA1 gene promoter contains many motifs with a relevant role in ex-
pression regulation.
Regulation sequences are located for 221 bp upstream of exon 1, as com-
mon as in many genes, and for 24 kb inside IVS1.
Between exon 1 and 2 there is an alternative exon, called exon 1a, 136 bp
in length and localized 2210 bp upstream of exon 2 [49]. This alternatively
spliced transcript encloses the complete coding sequence and is expressed in
testis and liver but not in macrophages [50]. Upstream of exon 1a an alter-
native promoter containing a TATA box and a CAAT box sites is present,
together with other potential binding sites for nuclear receptors containing
sterol regulatory elements.
1.2.1 Gene expression regulation
ABCA1 gene has ubiquitous expression and in basal conditions is mostly
translated in tissues like placenta, lung, liver, kidney, intestine, adrenal gland
and some areas of the nervous system. A high expression is present in the
same tissues also during the fetal development [11].
Many different factors are responsible of ABCA1 gene expression or in-
hibition and some of them are tissue-specific.
First of all, ABCA1 expression is markedly induced by overloading cells
with cholesterol, especially in macrophages [51,52]. This induction occurs ex-
clusively through activation of the nuclear receptors liver X receptor (LXRα
and/or LXRβ) and retinoid X receptor (RXR). LXR and RXR form obli-
gate heterodimers that preferentially bind to response elements within the
ABCA1 gene promoter and the first intron. LXRs and RXRs bind to and
are activated by oxysterols and retinoic acid, respectively. 9-cis retinoic
acid (9-cisRA), either alone or in combination with oxysterols, is the major
retinoic acid that upregulates ABCA1 mRNA levels. The LXRα gene pro-
moter in human macrophages contains a LXR responsive element, indicating
that LXRα can autoregulate its own expression; this would serve to amplify
the effects of oxysterols on the ABCA1 lipid eﬄux pathway. Because uptake
of non-oxidized cholesterol by cells increases ABCA1 expression, cholesterol
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must be converted to oxysterols before inducing ABCA1. It is believed that
22-hydroxycholesterol, 24-hydroxycholesterol, and 24(s),25-epoxycholesterol
are the major naturally occurring liver LXR ligands. Most oxysterols are
generated by cytochrome P-450 enzymes that are particularly prevalent in
the liver and play a role in bile acid metabolism. One of these enzymes,
sterol 27-hydroxylase (Cyp27), is broadly distributed in various tissues and
cell types, including macrophages, suggesting that 27-hydroxycholesterol is
the major LXR ligand in macrophages and other peripheral cells.
A sterol-responsive element has been mapped to an imperfect Direct
Repeat (AGGTCA) spaced by four nucleotides (DR-4) which was shown
to bind LXR/RXR heterodimers; mutations of the DR4 element strongly
reduced oxysterol-responsive ABCA1 gene activation [53,54].
The induction of ABCA1 gene transcription activity by 25-hydroxycholesterol,
another important stimulator of ABCA1 expression, is critically dependent
on Sp1 elements and an E-box motif present in the proximal promoter region
of ABCA1, 147 bp upstream of the originally identified transcriptional start
site.
The two ABCA1 promoters, upstream exon1 and inside intron 1 respec-
tively, contain other transcription regulators like a TATA box located 24 bp
upstream the transcriptional start site, essential for the promoter activity.
Lipid metabolites other than sterols can modulate ABCA1 expression by
the LXR system [49]:
• Polyunsaturated fatty acids act as antagonists to oxysterol binding
to response elements in the LXRα gene, potentially interfering with
induction of ABCA1 by sterols.
• Geranylgeranyl pyrophosphate (GGPP), a product of the mevalonate
pathway which isoprenylates proteins, was shown to suppress LXR-
induced ABCA1 synthesis by two mechanisms: as an antagonist of
the interaction of LXR with its nuclear co-activator SRC-1 and as an
activator of Rho GTP-binding proteins. This second mechanism might
alter sterol trafficking in cells, reducing their availability as ligands for
LXR.
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• Activators of Peroxisome Proliferator Activating nuclear Receptors (PPARs)
also enhance ABCA1 transcription in some cells and stimulate choles-
terol eﬄux by activating transcription of the LXRα gene through a
complex interaction between PPARα, PPARγ and LXRα, which in
turn induces ABCA1 transcription [55,56].
• Thyroid hormone receptor was reported to suppress ABCA1 transcrip-
tion by forming a complex with RXR that competes for LXR/RXR
binding to its response elements.
• ABCA1 transcription is also regulated by factors independent of LXR/RXR:
membrane-permeable analogs of cAMP and inhibitors of cAMP-specific
phosphodiesterase 4 stimulate ABCA1 transcription in macrophages
by unknown mechanisms; cAMP act in these cells by promoting the
binding of Sp1 and E-box binding factors to the proximal promoter
of ABCA1 thus stimulating ABCA1 gene transcription and surface
expression in absence of cholesterol, whereas ABCA1 expression in fi-
broblasts is critically dependent on cholesterol loading [57,58].
• The calcium channel blocker verapamil can also enhance ABCA1 tran-
scription by an LXR-independent process [59].
The ABCA1 gene promoter contains other transcriptional response elements
that are potential sites of regulation, some of which may influence constitu-
tive and tissue-specific expression of ABCA1: cytokines such as interferon-γ
(IFN-γ), along with a two-fold increase in the activity of acylcoenzyme A:
cholesterol acyltransferase (ACAT) decreases ABCA1 mRNA in macrophages
under basal conditions as well as after sterol-loading. This results in a two-
fold decrease of cholesterol effux [60,61].
Transforming growth factor β1 (TGF-β) and oncostatin M have been re-
ported to modulate ABCA1 transcription in cultured macrophages and hep-
atoma cells. Sterol regulatory element binding protein 2 (SREBP2), a tran-
scription factor that regulates sterol synthesis, appears to interact with the
ABCA1 promoter in vascular endothelial cells and to suppress ABCA1 tran-
scription, thus providing an additional mechanism for suppressing cholesterol
eﬄux when cells are sterol depleted [13].
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It has also been demonstrated a role of LDLR in regulation of ABCA1
expression as illustrated below (see 1.6.2).
Moreover negative control elements binding the transcriptional repres-
sor zinc-finger protein 202 (ZNF202) are thought to counterbalance ABCA1
mRNA expression and may be influenced by the genetic background. ZNF202
requires the presence and of a SCAN domain that mediates selective hetero-
and homodimerization and of a functional TATA box to bind to in order to
repress ABCA1 expression.
[Warning: Image ignored]
Figure 1.5: Regulation of the ABCA1 gene promoter.
Catepsine D (CTSD), a lysosomal proteinase, is another regulator of
ABCA1 expression: it increases both ABCA1 mRNA expression and cel-
lular ABCA1 protein, while its inhibition results in ABCA1 retention in
lysosomal compartments, reducing its traffic to the plasma membrane [62].
CTSD expression is regulated by NPC1 activity in hepatocytes: NPC1-null
hepatocytes show increased CTSD expression, both transcriptionally and
post-transcriptionally and this therefore has an effect on ABCA1 expression
and protein production [63].
Recently, ORP8, a protein belonging to OSBP (oxysterol-binding pro-
tein) and ORP (OSBP-related) gene family, was shown to negatively regulate
ABCA1 transcription by a mechanism involving DR4 and E-box elements
[64]. Since ORP8 is anchored to the ER by a C-terminal transmembrane do-
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main, transcriptional inhibition is probably indirect and related to the sterol
binding or metabolic activity of this ORP.
1.2.2 Post-transcriptional regulation
The first proposed mechanism of ABCA1 post-transcriptional regulation oc-
curs by phosphorylation of residues in the regulatory domain by protein
kinase A (PKA) following cAMP stimulation.
IFNγ appears to suppress ABCA1 expression by further destabilizing its
mRNA: the kinetics of ABCA1 mRNA and protein decrease is consistent
with the early IFN-γ-induced changes in Stat1 phosphorylation and nuclear
translocation. Therefore, down-regulation of ABCA1 by IFN-γ is a post-
transcriptional response that occurs early in the process of IFN-γ-induced
macrophage activation [65].
1.2.3 Post-translational regulation
Several processes that modulate ABCA1 protein stability have been de-
scribed and there is not always a strict correlation between ABCA1 mRNA
and protein levels.
When ABCA1 inducers are removed in the absence of apolipoproteins,
ABCA1 mRNA and protein are degraded at a fast rate (half-life of 1–2 h)
[66,67].The rapid protein turnover is largely due to a sequence at amino acids
1283–1306 in the first intracellular loop that is enriched in proline-glutamate-
serine-threonine (PEST motif). Phosphorylation of T1286 and T1305 in this
motif promotes ABCA1 proteolysis by an unknown member of the calpain
protease family. There are several metabolic factors that modulate the rate of
ABCA1 protein degradation by either this calpain system or other processes.
The interaction of apolipoproteins with ABCA1-expressing cells dramat-
ically reduces the rate of ABCA1 protein degradation by inhibiting ABCA1
proteolysis by calpain [66] and activating other signaling events that sta-
bilize the protein [68]. This regulation acts as a feedback mechanism to
sustain ABCA1 levels when acceptors for cellular lipids are available. First,
the cellular interactions of apolipoproteins interfere with the phosphoryla-
tion of the PEST motif. Second, the removal of membrane sphingomyelin by
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apolipoproteins activates phosphatidylcholine phospholipase C, which sig-
nals phosphorylation of ABCA1 at a site that stabilizes the protein [69].
It is unknown if either or both of these mechanisms require apolipoprotein
binding to ABCA1.
Unsaturated free fatty acids directly destabilize ABCA1 protein in cul-
tured cells by a signaling pathway involving activation of phospholipase D2
and protein kinase Cδ and phosphorylation of ABCA1 serines [67,70-72]
[71,74-76].
ABCA1 also interacts with β1- and α1-syntrophin, scaffolding proteins
that regulate transport through linkage to the cytoskeleton, resulting in sta-
bilization at intracellular sites and the plasma membrane [73,74].
Oxisterol binding protein (OSBP) is implicated in the integration of sterol
sensing/transport with sphingomyelin synthesis and cell signaling. OSBP
negatively regulates ABCA1 by decreasing its stability in the cytoplasm;
this effect is not correlated with OSBP function in sphingomyelin synthesis
or interaction of OSBP with the ER or Golgi apparatus but is dependent on
OSBP sterol-binding activity [75].
The LXRβ/RXR complex also has a role in regulating ABCA1 activ-
ity: this complex binds directly to ABCA1 on the plasma membrane of
macrophages and modulates cholesterol secretion; when cholesterol does not
accumulate, ABCA1-LXRβ/RXR localizes on the plasma membrane but
is inert; when cholesterol accumulates, oxysterols bind to LXRβ and the
LXRβ/RXR complex dissociates from ABCA1, restoring ABCA1 activity
and allowing apoA-I dependent cholesterol-eﬄux. Upon binding oxysterols
in the cytosol, LXRβ/RXR is translocated to the nucleus and activates the
transcription of ABCA1 and other genes [76].
Moreover, recently Singaraja et al [77] highlighted that ABCA1 is ro-
bustly palmitoylated by the palmitoyl transferase DHHC8 at cysteines 3,
-23, -1110, and -1111 and that abrogation of palmitoylation of ABCA1 by
mutation of the cysteines results in a reduction of ABCA1 localization at
the plasma membranes and a reduction in the ability of ABCA1 to eﬄux
lipids to apoA-I. Thus, palmitoylation regulates ABCA1 localization at the
plasma membrane, and regulates its lipid eﬄux ability.
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1.3 Tangier Disease
1.3.1 Historical Notes
In the history of American literature, the name Tangier is usually associated
with the eccentric writer William Borroughs, who conceived some of his
novels in this Moroccan town on the Straight of Gibraltar.
At the beginning of 1960s, D. Fredrickson et al. [78] from the Na-
tional Institute of Health (USA) described a particular syndrome in two sib-
lings characterized by: hypertrophic yellow-grayish tonsils, limph adenopa-
thy, hepathosplenomegaly and sensitive-motor like peripheral neuropathy, in
association with almost complete absence of HDL-C in the plasma (Anal-
phalipoproteinemia). These two siblings belonged to a family living in the
Tangier Island, a small isle located in Chesapeake Bay, approximately 20
miles west of the eastern shore of Virginia (see Figure 6). The island was
discovered by the English explorer Captain John Smith in 1608 and owes its
name to the poetic imagination of the sailor, who was reminded by its wide,
sandy shores of the white dunes of the port of Tangier in Morocco [79].
After its discovery, the island was without a single inhabitant for the
next 78 years, until 1686 when John Crockett together with a few comrades
founded a settlement there. Except for a calamitous outbreak of cholera in
1886, nothing particular happened for the next 300 years, and the inhabitants
made a modest living from the fishery. Tangier Island was well insulated
from the mainland both economically and socially, so when Dr Fredrickson
traveled there in the early 1960s, he found only one road, one car and about
900 residents, many of them speaking a unique local dialect and bearing the
surname Crockett [79].
Because other three couples of siblings were found affected by the same
disease in Tangier Island, Fredrickson proposed the denomination “Tangier
Disease” (TD). The presence of many individuals affected in one family with-
out a vertical transmission of the phenotype, suggested a recessive transmis-
sion of this syndrome, as explained in the big pedigree originally described
by Fredrickson in 1964 [78].
The manifestation of this disease in the Tangier Island is likely the result
of a geographic isolation and of endogamy that happened among the in-
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habitants during 400 years, all descendents from the small group of English
refugees.
After the first description of Tangier Disease in 1964, many others fol-
lowed in different geographic regions (USA, UK, New Zeeland, Australia,
Switzerland, Germany, Poland, Italy, Canada, France, Spain, The Nether-
land, Pakistan, Japan and Egypt).
Figure 1.6: Tangier Island. North-East coast of United States and Chesapeake Bay
with Tangier Island.
1.3.2 Case history of Tangier Disease
The phenotypic, pathognomonic case history that allowed the identification
of the first cases of Tangier Disease was the association of almost total ab-
sence of HDL-C in the plasma and presence of yellow-grayish tonsils [46].
The clinical phenotype of Tangier Disease has autosomic recessive trans-
mission. However the biochemical phenotype (very low HDL-C and apoA-I
levels) has a co-dominant transmission [81], that obligate heterozygotes have
HDL-C and apoA-I levels intermediate between normal values and those of
Tangier patients, but do not present any clinical feature.
Tangier Disease is characterized by two different biochemical alterations:
• Cholesteryl Esters (CE) accumulation in many cell types, especially
in histiocytes and in the reticuloendothelial system (aka: mononuclear
phagocyte system);
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• Almost total absence of HDL-C in plasma.
Cholesteryl Esters accumulation is particularly evident in tonsils, lymph
nodes, bone marrow, liver, intestine and Schwann cells of the peripheral
nervous system.
At a morphological level, histiocytic cells (e.g. macrophages) appear like
foam cells with the cytoplasm full of lipid droplets, which can be highlighted
with Sudan red/black, sometimes with crystal structures. This lipidic mate-
rial is formed by esterified cholesterol accumulated outside lysosomes.
The serious HDL defect is considered as a predisposition factor for car-
diovascular diseases (angina pectoris, myocardial infarction, stroke etc.) on
atherosclerotic base [53].
The phenotypic manifestations differ among individuals but symptoms
may be hypertrophic tonsils, hepatosplenomegaly, anemia, thrombocytope-
nia, stomatocytes, peripheral neuropathy and increased incidence of cardio-
vascular disease, whose clinical penetrance is however extremely variable [48];
the most represented feature is anyway tonsils hypertrophy, with typically
yellow-grayish lobulated tonsils, and hepatosplenomegaly [84]. Obviously,
tonsillectomy and therefore absence of tonsils can complicate the diagnosis.
Two major reports that dealt with this issue, published prior to the
time that the ABCA1 gene was identified, indicated that despite the near
absence of HDL, CVD (cardiovascular disease) only represents a significant
problem in middle age and elderly TD patients (over 35 years) [84,85]. Taken
the epidemiological evidence that a drug-induced increase of 1% in HDL-
C concentration may be associated with as much as 3% decrease in death
or myocardial infarction incidence, it is nevertheless remarkable that TD
patients with HDL-C below the 5th percentile (for age and sex) do not
appear to develop CVD until the age of 35-40 and some of these patients
live well into their seventies. One factor that has been brought forward to
explain this is the very low level of LDL-C found in TD patients but this
hypothesis has not yet been confirmed. Anyway the Italian patients with
TD, diagnosed up to now by our group (≈ 30 patients), show a marked
predisposition in developing premature atherosclerosis.
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1.3.3 Familial HDL Deficiency
Familial HDL deficiency (FHD) is a more common disorder of lipid metabolism
than Tangier disease, characterized by isolated moderate reductions of HDL-
C in absence of the typical characteristics of clinically evident TD. Recently
Frikke-Schmidt et al. revealed that i) approximately 10% of individuals with
the lowest percentile of HDL cholesterol in the general population are het-
erozygous for mutations in ABCA1 and ii) the frequency of FHD caused
by ABCA1 mutations in the general population is about three in 1000 or
considerably higher than previously assumed [87].
1.3.4 Cellular defects in Tangier Disease and Familial HDL
deficiency
The Cholesteryl Esters accumulation in many different cell types of the retic-
uloendothelial system suggested that in TD a defect of cholesterol intracellu-
lar traffic is present. This hypothesis was sustained by a series of experimen-
tal evidences obtained from dermal fibroblasts and monocyte-macrophages
in TD patients. TD fibroblasts when overloaded with cholesterol (after in-
cubation with acetylated LDL or free cholesterol) show a defect in phospho-
lipid and cholesterol eﬄux to plasma apolipoprotein acceptors (e.g. apoA-I,
apoA-II, apoC or apoE) [88-90].
1.3.5 Mutations on ABCA1 gene, Tangier Disease and Fa-
milial HDL deficiency
Until genetic bases of TD and FHD were unknown, patients were diagnosed
on the basis of their clinical phenotype. The discovery of the cellular defects
characterizing TD and FHD patients initiated a virtual race to identify the
molecular background responsible for the clinical and biochemical pheno-
type, and in 1999 three groups independently reported that homozygosity
and heterozygosity for mutations in ABCA1 caused Tangier disease and the
milder form, Familial HDL deficiency (FHD), respectively [6-8].
Through the usage of genetic markers (wide genomic screening) in many
Tangier families and the application of strict criteria for the biochemical
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phenotyping of heterozygotes, the “Tangier gene” was localized via linkage
studies on the long arm of chromosome (9q31) [51].
The further refinement of linkage studies and the differential analysis of
mRNA in wild type and TD macrophages when overloaded with cholesterol,
led to the identification of ABCA1 as involved in TD [6-8].
Since this discovery, the diagnosis of TD and FHD has been obtained
through analysis of genotype. Currently, the phenotypic variability of TD
is evident, with some TD patients showing very low HDL levels (<1%) and
others with HDL levels >10%.
Knowing the mutations characterizing affected patients, it is now possible
to determine functional deficits for a certain phenotypic spectrum associated
both with heterozygotes and homozygotes.
Nowadays ABCA1 genetic analysis is a key element in TD and FHD diag-
nosis and can represent an important instrument for a wider comprehension
of ABCA1 role in many pathways.
The investigation technique mainly used is the systematic sequencing of
all exons: the spread of mutations identified along ABCA1 gene up to now
forbids the restriction of the analysis area. The presence of 50 exons and 49
introns, for a total of 149 kb, transforms the complete sequencing in a long
procedure that requires on average one month for the diagnosis of a single
proband. For these reasons it is important to create a rapid, automated and
standardized pre-screening system in order to reduce the sequencing phase
to a low group of exons.
Some years ago we set up a technology that resembles these requirements
through the usage of Denaturing High Performance Liquid Chromatography
(DHPLC). This method allows the selection of those amplicons which show
abnormal elution profiles (on average 10-15 amplicons in ABCA1 case) and
thus the restriction of the following sequencing procedure [80].
1.3.6 ABCA1, Ischemic Heart Disease and atherosclerosis
Numerous population studies have shown an inverse relationship between
plasma HDL levels and CVD risk, implying that HDL protects against
atherosclerosis [81]. It is therefore clear that the relative activity of ABCA1
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plays a role in this atheroprotective mechanism. The low plasma HDL levels
identified in individuals with impaired ABCA1 pathway would also promote
accumulation of cholesterol in tissue macrophages and perhaps increase local
inflammation. It has been also demonstrated that ABCA1 over-expression
protects against atherosclerosis in ApoE-/- mice, a strain that spontaneously
develop atherosclerotic lesions [28].
Subjects with loss-of-function homozygous or compound heterozygous
mutations in ABCA1 (Tangier disease) have a 4–6-fold higher than normal
incidence of CVD, which applies equally to both men and women. This mod-
erately high risk for atherosclerosis is not as dramatic as one would expect for
individuals with a virtual absence of HDL. A thorough review of all known
Tangier disease patients worldwide reported that only 20% of patients had
atherosclerotic manifestations, thus emphasizing a huge discrepancy between
the virtual absence of plasma HDL cholesterol in these homozygotes and the
lack of the expected large increase in risk of cardiovascular disease, predicted
from epidemiological studies [82].
Their low levels of LDL (40–60% normal) may partially protect these
subjects from atherogenesis. Some subjects with common ABCA1 variants
have been reported to have premature CVD. However, the number of iden-
tified Tangier disease patients is very low and not all individuals with the
same ABCA1 variant show signs of CVD. Therefore, it is difficult to draw
firm conclusions about the cardio-protective role of ABCA1 so far.
Studies of ABCA1 heterozygotes, which tend to have more normal lev-
els of LDL, have produced ambiguous results. Analyses of a small number
of FHD patients showed significant increases in CVD and carotid artery
intima media thickness when compared to control subjects and these in-
creases were associated with impaired ABCA1-dependent cholesterol eﬄux
from their cultured fibroblasts. These studies strongly support the idea that
impaired ABCA1 increases atherosclerosis in humans, but not in all cases
and by mechanisms that may not reflect reduced HDL levels. A huge study
with total of 41,961 participants from the Danish population including 109
ABCA1 heterozygotes and 6666 IHD (Ischemic heart Disease) cases, were
ascertained and it was showed that heterozygotes for four loss-of-function
mutations had lower levels of HDL cholesterol and apoA-I than non-carriers
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but plasma triglycerides and remnant cholesterol did not differ; low plasma
levels of HDL cholesterol due to heterozygosity for these four mutations were
not associated with an increased risk of IHD [81].
There are several possible reasons for these variable responses to ABCA1
mutations. First, many ABCA1 heterozygotes have only modest reductions
in plasma HDL levels and ABCA1 cholesterol export activities, thus the
defects may not be significant enough to accelerate CVD in all individuals.
Second, most of the HDL is produced by liver ABCA1, which may not reflect
the activity of ABCA1 in arterial macrophages. Third, impairment of other
ABCA1 functions, such as anti-inflammation, could have bigger impacts on
atherogenesis than reduced cholesterol export, especially in individuals prone
to enhanced inflammatory responses [34].
Recently Frikke-Schmidt highlighted that because data from observa-
tional studies of the inverse relationship between low HDL-C levels and risk
of IHD is confounded by high triglycerides, marking the presence of athero-
genic remnant lipoproteins, and because genetically low HDL-C per se does
not translate into the expected increase in risk, low levels of HDL cholesterol
as a primary causal factor in the pathogenesis of IHD needs re-evaluation
[82].
1.4 ABCA1 gene screening
1.4.1 Mutations identified up to the present in ABCA1 gene
Since 1999, when ABCA1 was identified as the main gene involved in TD
(see 1.3), over than 112 different mutations have been described http://
www.uniprot.org/uniprot/O95477 both in TD and FHD patients.
Among these variants, 76 are responsible of non conservative aminoacid
substitutions (missense mutations), 10 introduce a stop codon (nonsense mu-
tations), 20 are small insertions or deletions and 6 are splice-site variations.
There is therefore a heterogeneity of mutant alleles that requires sequenc-
ing of the entire ABCA1 gene when a new case of TD or FHD is found, in
order to identify the causative mutation. All variants that cannot be referred
as frequent polymorphisms (SNPs) usually lead to a reduction of lipid eﬄux
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from peripheral cells.
Even if ABCA1 mutations are distributed along the entire gene, their
localization is not random. Most of variants functionally studied so far are
localized on the two large extracellular loops.
1.4.2 Biological impact of ABCA1 mutations
Due to the complexity of ABCA1 gene, the protein size and the high allelic
heterogeneity observed, it is really hard to define the biological meaning of
each mutation identified.
Despite these limitations, some hypothesis have been proposed to explain
the functional defect depending on the position of a certain mutation.
Mutations in the extracellular loops: approximately half of missense mu-
tations in ABCA1 gene associated with TD and FHD fall within the 2 extra-
cellular loops. Mutations in the first and second extracellular loops might be
expected to result in a lack of lipid eﬄux caused by dysfunctional interaction
of ABCA1 with apoA-I; the lipid-poor pre-β-HDL particles would require ei-
ther direct interaction or close proximity to ABCA1 for the lipid transfer to
occur. It is also possible that mutations in the extracellular domains will
result in a disruption of the tertiary structure of ABCA1, preventing its
function at the plasma membrane where it is normally localized.
Mutations in the transmembrane domains: mutations in the transmem-
brane domain region have been proven to disrupt the integration of ABCA1
into membranes and therefore prevent it from exiting the endoplasmic retic-
ulum and the Golgi and its integration into the plasma membrane. This
could result in the rapid turnover of the mutant ABCA1 protein.
Mutations in the Nuclear Binding Domains: it has been demonstrated
that mutations at this level avoid ATP binding and hydrolysis and there-
fore ABCA1 ability to mediate cholesterol eﬄux but this doesn’t mean that
ABCA1 is unable to reach the cell surface. Moreover, mutations in the NBDs
lead to an impairment of ABCA1 oligomerization as explained before [42].
Mutations at the C-terminus: ABCA1 C-terminus is critical because
containing a PDZ binding domain [83,84] that, if mutated, leads to protein
mislocalization. Both the PDZ binding motif and the VFVNFA sequence
1.4. ABCA1 GENE SCREENING 27
located at positions 2210–2215 have been identified as potential interac-
tion sites for homodimers creation, the predominant ABCA1 organization
[73,84,85]. They may be required either to stabilize the dimeric interaction
or to introduce additional molecular partners in the complex. It is therefore
possible that an alteration of the C-terminus blocks ABCA1 oligomeriza-
tion [42]. Only few mutations in this domain have been identified and/or
characterized so far.
1.4.2.1 Polymorphisms and their biological value
Due to its dimensions, it is not surprising that ABCA1 gene presents many
polymorphisms, the most common shown in Appendix B. SNPs analyses
have identified over 20 common polymorphisms (>1% allele frequency) in
the coding, promoter and 5’UTR regions of ABCA1 and several of these are
associated with either low of high HDL-C plasma levels [34]. It is likely that
other polymorphisms are present in ABCA1 introns. The functional meaning
of polymorphisms positioned in the promoter, especially in the proximity of
the transcription start site, is unknown.
Many exonic polymorphisms lead to conservative aminoacid substitu-
tions. The functional role of these common substitutions is not clear; some
of them are related to changes in HDL plasma levels. For instance, ho-
mozygotes for I883M variant have HDL plasma levels significantly increased
compared to normal population [86,87]. Heterozygotes for R219K variant
(46% of North-central European subjects) have lower triglyceride levels and
higher HDL levels than controls. They also seem to show fewer vascular
atherosclerotic alterations and a lower number of coronary events.
Polymorphisms make the genetic investigation for causative mutations
more difficult. Moreover, intronic variants which meaning is unknown (pos-
sible splice-site variations etc.) are quite common.
The study of extreme phenotypic groups from a general population sam-
ple has increased the chance of identifying genetic variants with effects on a
specific phenotype. Frikke-Schmidt et al. showed that common variants on
ABCA1 gene may be differentially distributed in the extreme tails of HDL
levels and that these SNPs are most likely to be associated with the level of
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this specific trait in the general population. From this screening approach it
was evident that common variants are present in both extreme groups but
tend to differ in frequency if they affect the specific phenotype, whereas a
rare variant with a strong phenotypic effect is more likely to be observed in
only one extreme [88-91]
1.4.2.2 Biological effect of mutations: genotype to phenotype cor-
relation
An investigation on the relationship between discrete mutation and pheno-
type is instrumental in understanding what governs the variable penetrance
of clinical signs in Tangier pedigrees.
As direct genotype/phenotype correlations are impossible due to the rar-
ity of the disease, alternative approaches such as the generation of appro-
priate animal models exclusively expressing informative ABCA1 mutants or
ex vivo and in vitro studies have to be envisioned. Finally, as ABCA1 can
be considered one of the most clearly identified therapeutic targets in the
prevention of cardiovascular disease, several efforts have arisen in the aim of
predicting how and whether genetic polymorphism may contribute to differ-
ences in phenotypic traits.
Not always aminoacid variants on ABCA1 protein lead to a pathogenetic
effect. In order to clarify the repercussion that a certain variant has on
ABCA1 function, intracellular traffic and localization, it is necessary to func-
tionally characterize it.
Knockout mice demonstrated that ABCA1 dysfunction is sufficient to
generate hypolipidemic profiles [90,92-94]: they faithfully reproduce the hu-
man syndrome; however, a few traits appear limited to the mouse models.
First, the engulfment of cells dying by apoptosis is clearly impaired during
embryonic development in the mice. This defect, which is devoid of major
developmental consequences, has obviously not been investigated in humans.
In addition, ABCA1−/− females are infertile due to impaired placental de-
velopment, a phenotype related to the high expression level of ABCA1 in
the pregnant uterus. A similar sign is lacking in human Tangier patients
though an increased incidence of spontaneous abortions has been informally
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recorded. Although the alterations in metabolic profile and most phenotypes
related to ABCA1 loss of function appear robust and background-insensitive,
exquisite differences in the ABCA1 expression indeed exist between the var-
ious mouse strains. The invalidation of ABCA1 gene in mice leads also
to clinically relevant phenotypes unrelated to lipid metabolism; these span
from aberrant responses to malaria infection to increased development of
Alzheimer’s related degenerative lesions.
Another method involves patients’ derived cells, either fibroblasts or
monocytes-macrophages or immortalized lymphocytes.
Immortalized lymphocytes show the advantage of a long-lasting mainte-
nance but show a weak ABCA1 expression and are hard to immortalize and
maintain in culture [95,96].
Fibroblasts are the most investigated patient-derived cells and show a
good ABCA1 expression, but they are not always available, collection re-
quires an invasive approach and their culture is complex [97-100]. The usage
of dermal fibroblasts may produce some other limitations, especially if the
proband is a simple heterozygote, thus carrying a wild type allele, or a com-
pound heterozygote, thereby with two different mutant alleles.
Monocyte-macrophages instead are isolated from blood without invasive
approaches and easily cultured [99,101,102].
Another way to investigate the effect of a novel ABCA1 variant on the
protein function is that of using in vitro studies via transfection of heterol-
ogous cells with mutant cDNA.
Transfection of mammal cells with mutant cDNA allows overcoming all
the problems listed above, leading to the analysis of the only mutant desired.
The main issue in choosing the transfection method is to obtain a specific
mutant cDNA containing the only mutation of interest and able to create a
mutant protein identifiable inside the cells. This problem arises in particular
for ABCA1, due to the gene dimensions, a discouraging factor for the analysis
of missense mutations. However the new mutagenesis technologies overcome
this matter so that more and more researchers are applying in vitro studies
for the functional analysis of novel ABCA1 missense mutations in order
to clarify the biological role of specific ABCA1 protein domains (Walker
domains, extracellular loops, apoA-I binding sites, carboxi-terminal region
30 CHAPTER 1. INTRODUCTION
etc.) [30,73,97,103-109].
It should be remarked anyway that transfection technologies induce an
over-expression of ABCA1 gene in the host cells, which does not resemble the
most physiological situation since it could generate some aspecific responses
like ERAD (ER-Associated Degradation) and UPR (Unfolded Protein Re-
sponse). Whenever possible, ex-vivo studies should be therefore preferred or
at least performed in parallel with in vitro studies [110-113].
It is anyway difficult to generalize the relation between the position of
a certain variant on ABCA1 protein domains and its biological effect on
ABCA1 structure and function.
1.5 Cell cholesterol homeostasis
Mammalian cells require cholesterol for maintenance of membrane integrity
and multiple cellular functions [114]. Cholesterol is vital to several cellular
processes, including cell growth, gene regulation, and synthesis of lipopro-
teins, steroid hormones, and bile acids [115]. However, an excess of intra-
cellular free cholesterol could be toxic for the cell. Moreover, cholesterol is
important in the pathogenesis of cardiac and brain vascular diseases, in de-
mentias, diabetes and cancer as well as in several rare monogenic disorders.
For these reasons the amount and distribution of intracellular and whole-
body cholesterol are tightly controlled processes. Since lipids are not geneti-
cally encoded, genome and transcriptome changes can only reflect cholesterol
homeostasis indirectly; many of the proteins that preserve cellular cholesterol
homeostasis exhibit considerable functional redundancy [116] thus leading to
the conclusion that the organism needs a huge regulatory apparatus to finely
tune cholesterol balance.
1.5.1 De novo cholesterol synthesis
The major sources of cellular cholesterol are represented by: i) de novo
synthesis and ii) uptake of cholesterol from circulating lipoproteins.
All cells of the body can synthesize cholesterol; synthesis occurs in the
Endoplasmic Reticulum (ER) compartment where the synthesis apparatus
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is located. The rate-limiting step of the synthetic pathway is the conver-
sion of HMG-CoA to mevalonate mediated by the HMG-CoA Reductase
enzyme (Fig. 1.7). HMG-CoAR, similarly to other enzymes that function in
the later steps of cholesterol synthesis, is an integral ER membrane protein
[116]; it is composed of 8 TM domains and it contains (between TM and 6)
a “Sterol Sensing Domain” (SSD), a conserved motif common also to sev-
eral key proteins involved in cellular cholesterol metabolism regulation like
SCAP, NPC1, SREBPs, Insigs. This domain allows to “sense” the cholesterol
content of the ER membrane and to consequently regulate the synthetic rate
of cholesterol.
HMG-CoAR is regulated, at the transcriptional level, by SREBPs (a
group of proteins which mainly regulate cholesterol synthesis and uptake,
as illustrated in 1.5.2.2); gene transcription is suppressed by intracellular
cholesterol accumulation. At the post-transcriptional level the reductase is
regulated by sterol-accelerated degradation: in particular in sterol-deprived
cells HMG-CoAR is slowly degraded, while when sterols accumulate, the
enzyme is rapidly ubiquitinated and degraded with an half-life of less than
1 hour. Both regulation processes are mediated by Insigs as described in
section 1.5.2.2 [115].
1.5.2 Cholesterol uptake (influx) and endosomal cholesterol
traffic
The alternative and preferred source for cellular cholesterol acquisition is
the uptake of lipoproteins from the circulation through a receptor-mediated
mechanism. The process is mediated by the cell surface LDL Receptor
(LDLR) which binds plasma lipoproteins containing ApoB or ApoE (mainly
LDL but also VLDL and chylomicron remnants). Lipoprotein particles, once
bound to the receptor, are internalized via clathrin-coated pits; these vesicles
then fuse with early endosomes where the lower pH allows the dissociation of
LDL from LDLR. The LDLR is then localized to a recycling endocytic com-
partment, which transfers back the receptor to the cell surface. Cholesteryl
esters contained in the internalized LDLs are hydrolyzed in late endosomes
and lysosomes by an acid activated enzyme, namely LAL (lysosomal acidic
32 CHAPTER 1. INTRODUCTION
Figure 1.7: Cholesterol synthesis.
lipase), which generates free cholesterol.
1.5.2.1 LDLR structure
LDLR molecule is a glycoprotein of 839 aa, including 5 functional domains:
i) a ligand binding domain at the NH2 side; ii) an Epidermal Growth Factor
(EGF) homology region; iii) an “O-linked” oligosaccharide-rich region; iv) a
TM domain; v) a cytoplasmatic tail at the COOH side (Fig. 1.8).
1. The ligand binding domain is organized in 7 repeated motifs, each
one containing a cysteine-rich region important for the maintenance
of the proper 3D folding. The conformation of the ligand binding
domain ensures the exposure of negatively charged groups which allow
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the interaction with the positively charged groups of the ApoE and
ApoB100 proteins.
2. The EGF precursor homology region includes three regions (A, B and
C); it is involved in the acid-dependant conformational change needed
for the dissociation of the receptor to LDLs, which occurs in endosomes.
Moreover it has been recently reported that a post-transcriptional reg-
ulator of LDLR, PCSK9, is able to bind to LDLR in this region [117]
and to drive it to lysosomal degradation.
3. The “O-linked” oligosaccharide-rich region is a domain rich in threonine
and serine, but its function is still unknown; it might be involved in
the overall stabilization of the molecule.
4. The TM domain is necessary for the anchorage of the receptor to the
cell surface since any mutant devoid of this domain results in a secreted
form of the protein.
5. The cytoplasmatic tail of the receptor is highly conserved among dif-
ferent species and its role is mainly related to the positioning of the re-
ceptor on the “coated pits” on the cell surface. The proper localization
of the receptor allows the binding and the subsequent internalization
of LDLs since natural or artificial mutants of this domain are able to
bind LDLs but not to mediate their endocytosis.
Lipoprotein uptake occurs in all cells of the organisms but has its main signif-
icance in hepatocytes where lipids and TG can be used for VLDL synthesis
or driven for excretion with the bile.
1.5.2.2 The SREBP-SCAP system
Both cholesterol synthesis and uptake are transcriptionally regulated by
SREBP transcription factors. SREBPs proteins are a group of transcrip-
tion factors, which are present in three different isoforms in mammalian cells:
SREBP-1a, SREBP-1c, and SREBP-2. All three SREBPs are ER transmem-
brane proteins, shaped like hairpins with both the NH2-terminal transcrip-
tion factor domain and the COOH-terminal regulatory domain facing the
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Figure 1.8: LDLR structure. Schematic representation of LDLR structure.
cytosol. Immediately after their synthesis on ER membranes the SREBPs
bind to another transmembrane protein called SCAP (SREBP Cleavage Ac-
tivating Protein). SCAP is an SSD-containing protein, embedded in ER
membranes through its 8 TM domains.
When cholesterol is abundant, building up also in ER membranes, the
sterol binds to SCAP, inducing a conformational change that causes SCAP
to bind to a third protein called Insig (Insulin Induced Gene protein 1), an
ER retention protein. In this way SCAP remains in the ER along with its
attached SREBP [115,118].
In sterol-depleted cells the SCAP/SREBP complex exits the ER in vesi-
cles that bud from ER membranes, thanks to a conformational change in
the sterol-sensing domain of SCAP, dissociating Insig and allowing SREBP-
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SCAP to reach the Golgi. Two proteases in the Golgi release the active form
of SREBP, which translocates to the nucleus to activate transcription of the
target genes [118]. SREBP bind to a highly conserved sequence, called SRE
(Sterol Responsive Element) located in the promoter region of both LDLR
and HMG-CoAR genes thus inducing their transcription.
With respect to the post-trancriptional regulation of HMG-CoAR, ac-
celerated degradation begins when lanosterol (a cholesterol precursor) ac-
cumulates in ER membranes. This accumulation induces the reductase to
bind to Insig-1, which is pre-associated with a complex of proteins, including
an ubiquitin ligase. These events trigger the ubiquitination and subsequent
proteasome degradation of HMG-CoAR.
Thus in regulating cellular sterol concentrations, nature has engrafted a
specific control mechanism upon two general processes; in both processes the
central regulator is the same protein, Insig [115] (Fig. 1.9).
Figure 1.9: Two Actions of Insigs in Cholesterol Homeostasis. Insigs regulate
ER-to Golgi transport of Scap/SREBP in a process that is inhibited by cholesterol. Insigs
also regulate the ubiquitin-mediated proteasomal degradation of HMG CoA reductase in
a process that is stimulated by lanosterol.
1.5.2.3 LDLR regulation
The SREBP/SCAP system ensures a tight regulation of the transcription of
LDLR, but LDLR is also regulated at a post-transcriptional level by other
mechanisms:
1. PCSK9 is a pro-protein convertase, recently discovered, whose role is
36 CHAPTER 1. INTRODUCTION
Figure 1.10: SREBP regulation of cholesterol metabolism.
to regulate LDLR number on the cell surface of hepatocytes. PCSK9
is secreted by the hepatocytes, binds to the extracellular EGF-A seg-
ment of the LDLR, is internalized through clathrin coated vesicles and
targets the LDLR towards the endosomal/lysosomal degradative path-
way [119]. Both the LDLR and PCSK9 are transcriptionally regulated
by SREBP-2. Thus, as more LDLR protein is produced, more PCSK9
is made, ultimately leading to the degradation of the LDLR protein in
hepatocytes. One possible explanation for this seemingly futile regula-
tory cycle is that PCSK9 might act as a ‘brake’ to slow the uptake of
LDL-derived cholesterol by degrading LDLRs. PCSK9 can potentially
avert excessive cholesterol accumulation within the cell by preventing
the recycling of LDLRs to the cell surface [120]. Its principal site of
action is the hepatocyte where PCSK9 molecule is mainly produced,
but its action is going to be elucidated also in extra-hepatic tissues.
2. The sterol sensitive nuclear receptor LXR regulates LDLR dependent
cholesterol uptake through a pathway independent of the SREBPs.
LXR induces the expression of Idol (a newly discovered protein named
Inducible degrader of the LDLR), which in turn catalyzes the ubiqui-
tination of the LDLR, thereby targeting it for degradation. Identifi-
cation of the Idol-LDLR pathway fills a gap in our understanding of
how LXRs control cholesterol homeostasis. The ability of LXRs to re-
spond to excess cellular cholesterol by promoting eﬄux through ABC
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transporters has been extensively documented. The LXR-Idol-LDLR
pathway provides a mechanism to simultaneously limit LDL choles-
terol uptake. Idol and ABCA1 are coordinately regulated by LXR in
a cell-type specific manner [121].
1.5.3 Intracellular cholesterol transport
Cholesterol derived from endogenous synthesis or uptake is differentially dis-
tributed in subcellular compartments. The ER is the crucial regulatory
compartment in cholesterol homeostasis, despite being a cholesterol-poor or-
ganelle. It has been estimated that less than 0,5-1% of total cellular choles-
terol is located in the ER membranes, but ER cholesterol levels can fluctuate
widely; perturbations resulting in modest changes in PM cholesterol, rapidly
translate into large changes in ER cholesterol pool, thus demonstrating that
cholesterol exchange between PM and ER is highly dynamic. For instance
when total cholesterol was increased two fold, the ER cholesterol content rose
to 5%; at these levels SREBP cleavage is suppressed, and both cholesterol
synthesis and uptake are blocked. Through ER cholesterol pool fluctua-
tions, cells are able to respond with great precision to changes in membrane
cholesterol and thereby to finely tune their cholesterol content [122,123].
Furthermore ER cholesterol pool is considered the main regulatory pool
because also cholesterol esterification, mediated by ACAT (Acyl-coenzyme
A:cholesterol acyltransferase) enzyme occurs in the ER. ACAT-mediated es-
terification of cholesterol limits its solubility in the cell membrane lipids and
thus promotes accumulation of cholesterol ester in the fat droplets within
cytoplasm; this process is important because it prevents the intracellular
accumulation of free cholesterol which is toxic for the cell. [116,118].
There are two general ways that cholesterol can move intracellularly,
vesicular and non-vesicular. Vesicular traffic typically requires an intact cy-
toskeleton, along which vesicles move, while non-vesicular transport can be
mediated by diffusible carrier proteins, with hydrophobic cavities to bind
cholesterol and transport it across the aqueous cytosol. The de novo synthe-
sized cholesterol leaves the ER rapidly thereby helping to maintain low ER
sterol content. The main destination of this “new” cholesterol is represented
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by the plasma membrane, which accounts for the 65-80% of total cellular
cholesterol. This movement of cholesterol is likely non-vesicular and sites
of close physical membrane apposition between ER and PM could facilitate
this transport [118].
The FC originated in late endosomes/ lysosomes from LDL-derived cholesteryl
esters, is distributed to other subcellular compartments through the coordi-
nated action of two important proteins, NPC1 and NPC2 (Niemann Pick
type C, 1 and 2). Both proteins can bind sterol but if NPC1 is a large glyco-
protein, comprising 13 TM domains (5 of which constitute a SSD), located in
endosomal membranes, NPC2 is a small soluble cholesterol-binding protein
located in the lumen of late endosomes and lysosomes. Their way of transfer-
ring and move cholesterol has not been fully elucidated but a model suggests
that NPC2 could transfer cholesterol from the inner endosomal membranes
to the outer endosomal membrane, where cholesterol eﬄux must occur, or
where NPC1 can “sense” it and mediate its transfer [118].
Despite their low cholesterol content, mitochondria are the site of some
important cholesterol-metabolizing enzyme, such as sterol 27-hydroxylase
(Cyp27). This enzyme converts cholesterol to 27-hydroxycholesterol, the
most abundant oxysterol in plasma. This oxysterol is: i) the first interme-
diate in the alternative pathway of bile acid synthesis from cholesterol; ii) a
more soluble transport form of cholesterol in plasma; iii) a potent repressor
of SREBP processing and iv) a partial LXR agonist. It is not clear how
cholesterol reaches the mitochondria, probably it could either derive from
the PM, either from endosomes, either from cytosolic lipid droplets [118].
1.5.4 Oxysterols
Oxysterols are oxygenated metabolites of cholesterol, present in low concen-
trations in mammalian cells, since they are more potent than cholesterol
itself in affecting critical genes in cholesterol turnover. Perhaps the best
support for this model is the existence of nuclear receptors that bind these
compounds with high affinity and the fact that oxysterols potently regu-
late the expression of sterol-sensitive genes in vitro. Furthermore formation
of an oxysterol is a mechanism by which some cells may eliminate excess
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cholesterol, since oxysterols are more soluble than cholesterol itself.
Besides 27-hydroxycholesterol, which is formed in the mitochondria by
Cyp27, other oxysterols like 25-hydroxycholesterol and 24,25- epoxycholes-
terol are formed during cholesterol synthesis in the ER. Although choles-
terol synthesis in isolated cultured cells can be suppressed by either exoge-
nous cholesterol or oxygenated cholesterol derivatives, several studies demon-
strated that oxysterols, rather than cholesterol itself, downregulate choles-
terol synthesis and uptake by the inhibition of SREBP cleavage. In par-
ticular, 25-hydroxycholesterol has been found to be one of the most potent
suppressors of sterol synthesis in cultured cells [124].
Moreover oxysterols are generally believed to be the most important
physiological activators for Liver X Receptors, the nuclear receptors which
regulate ABCA1 synthesis (see 1.2.1).
So oxysterols behave as important regulators of cholesterol homeostasis,
inhibiting cholesterol synthesis and uptake through their action on SREBP
processing, and promoting cholesterol eﬄux as LXR ligands.
1.5.5 Cholesterol eﬄux
The process of FC eﬄux has been extensively described above (see 1.1.3)
anyway in terms of cellular cholesterol homeostasis, it should be remarked
that: i) the formation of oxysterols is one of the crucial step in promoting cell
cholesterol eﬄux; ii) the availability of the substrate for ABCA1-mediated
eﬄux, represented by free cholesterol (FC) is also a limiting factor; iii) given
the first two issues, the third limiting concept is the accessibility of the FC
pool to ABCA1. Any perturbation in cell cholesterol homeostasis, resulting
in decreased oxysterol formation, reduced availability of FC or reduced ac-
cessibility of the FC pool to ABCA1 may result in an eﬄux defect, and lead
to intracellular cholesterol accumulation. This is the case of some mono-
genic disorders of cholesterol metabolism, in which the primary defect is not
in ABCA1 gene, but the clinical phenotype is often worsened by an eﬄux
defect, consequently leading to intracellular cholesterol accumulation and
HDL-C levels reduction in plasma.
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1.6 Monogenic disorders of cholesterol metabolism
and low HDL-C
Perturbations of CH homeostasis occur in several monogenic disorders such
as Niemann-Pick type C disease (NPC), Cerebrotendinous Xanthomato-
sis (CTX), Familial Hypercholesterolemia (FH). Despite different biochem-
ical defects affecting different intracellular cholesterol pathways, these dis-
orders share a common phenotype that is low levels of plasma HDL. This
HDL deficiency may suggest that the mechanisms of HDL formation via
ABCA1/ABCG1 mediated FC eﬄux is defective.
1.6.1 The NPC and CTX example: a systemic defect in HDL
levels due to a cellular defect in IC cholesterol trans-
port
Niemann Pick Type C (NPC) disease is a severe autosomal recessive
lipidosis characterized by the accumulation of unesterified cholesterol in the
endosomal/lysosomal system. Affected individuals show progressive neu-
rodegeneration and hepatosplenomegaly, and the disease is frequently fatal
in the first or second decade. The most prominent cellular feature is the
accumulation of unesterified cholesterol and glycosphingolipids in the late
endosome/lysosome compartment, as well as the trans-Golgi cisternae, and
a delay in the transfer of unesterified cholesterol to other intracellular des-
tinations. NPC disease is caused by mutations in two genes: NPC1, which
accounts for 95% of NPC patients, and NPC2, which accounts for the re-
maining 5% of patients [125].
In NPC patients, in addition to the severe phenotypic manifestations
listed above, plasma HDL-C levels were low (below 1 mmol/l or 40 mg/dl)
in 17 of 21 (81%) NPC disease patient fasting plasma samples studied [126].
It was demonstrated that these reduced levels of HDL-C, observed in NPC
patients, are the consequence of impaired ABCA1 regulation, rather than
mutation.
The defects in either the two proteins NPC1 and NPC2 cause the en-
trapment of FC in lysosomes, which is responsible for several downstream
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alterations (i.e. loss of feedback inhibition of cholesterol synthesis, lack of
down regulation of LDL-receptor expression, reduced formation of oxysterols
etc.), due to the inability of FC to down regulate the expression of SREBPs.
In addition the conversion of FC to oxysterols is impaired in NPC cells, re-
ducing LXR ligand availability and activation of LXR-dependent genes. In
NPC1 cells, expression of the ABCA1 transporter is reduced, resulting in
decreased FC eﬄux [126,127]. A recent study demonstrated that NPC1 has
an atheroprotective role in mice through regulation of LXR-dependent FC
eﬄux pathways, specifically mediated by ABCA1 and ABCG1 [128].
Figure 1.11: Expression of ABCA1 in human NPC1-deficient fibroblasts. A,
ABCA1 mRNA and protein levels; B, average ABCA1 protein levels in cells incubated in
absence or presence of free cholesterol [126].
Cerebrotendinous Xanthomatosis (CTX) is a neurodegenerative
disease due to the accumulation of cholesterol and cholestanol in the central
nervous system; the molecular defect resides in the lack of activity of sterol
27-hydroxylase (CYP27) which converts cholesterol to 27-hydroxycholesterol.
In the liver this enzyme is involved in the conversion of FC to bile acids, while
in other tissues the formation of 27-hydroxycholesterol plays a key role in
i) the activation of LXR, as this oxysterol is one of LXR ligands, and LXR
dependent gene expression (i.e. ABCA1 and ABCG1) [129]; ii) providing
a way of facilitating sterol eﬄux via the formation of a more hydrophilic
compound than cholesterol. In macrophages RAW264.7 ABCA1-mediated
FC eﬄux to apoA-I is induced by overexpression of CYP27A1 gene [130].
CTX patients have a complex phenotype, partly reflecting the impor-
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tance of CYP27 for bile acid synthesis. Thus, high levels of toxic bile acid
intermediates circulate in these patients. There are, however, other features
of CTX that are not readily explained by the bile acid biosynthetic defect but
are compatible with the notion of a defective formation of endogenous LXR
ligands. For example, intracellular cholesterol is elevated in CTX patients,
and premature atherosclerosis is relatively common despite low to normal
LDL cholesterol levels. A single study [131], reported very low HDL levels
in CTX patients. This would be expected if the absence of CYP27 caused
a low intracellular LXR tone leading to low ABCA1-mediated high density
lipoprotein formation.
Figure 1.12: ABCA1 and SREBP-1c expression in CYP27 deficient fibroblasts
ABCA1 and SREBP-1c gene expression in normal and CYP27-deficient human fibroblasts:
response to cholesterol loading [129].
1.6.2 Familial Hypercholesterolemia: cholesterol influx de-
fect and intracellular defects
Familial Hypercholesterolemia (FH) is an autosomal codominant dis-
ease caused by mutations in LDLR gene. FH heterozygosity is retrieved
in the general population at a frequency of about 1:500; these patients
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show high levels of total cholesterol (from 350 to 450 mg/dl) and LDL-C
in plasma, tendon xanthomas, premature atherosclerosis. FH homozygotes
(1:1.000.000) have extremely high levels of total (600-1000 mg/dl) and LDL
cholesterol in plasma, xanthomas and a severe, accelerated and premature
atherosclerosis. Low levels of HDL-C are frequently observed in FH (HDL-
C 30,7 ± 9,5 mg/dL, [132]) but the molecular mechanism underlying this
defect has not been fully characterized.
In FH cell the defect in LDL-R prevents the uptake of plasma LDL and
the internalization of LDL-derived cholesterol. While the accumulation of
plasma LDL represents the major pathogenic factor in FH, the defective re-
ceptor mediated uptake of LDL derived cholesterol causes cell free-cholesterol
deprivation. This is responsible for the activation of SREBP transcription
factors which induce the expression of cholesterol related genes (i.e. HMG-
CoA reductase, LDL-receptor). SREBP has recently been described as a
negative regulator of ABCA1 expression and function in LDL-R-/- murine
macrophages. In particular SRPEB1a inhibits ABCA1 promoter activity in
an E-box independent and LXRE-dependent manner and ABCA1 expression
in animal tissues has been demonstrated to be inversely correlated to ac-
tive SREBP1. Oxysterols usually inactivate SREBP1 in macrophages, thus
strengthening ABCA1 activity but, if LDLR is absent, it is not able to insure
inhibition of SREBP1 proteolysis and this leads to an abnormal response of
SREBP1 processing of sterol [133]. This mechanism suggests that the low
HDL levels identified in FH patients, could be caused by a defect in ABCA1
regulation and function. Moreover it has been recently reported that mono-
cytes derived from FH homozygotes have a decreased expression of ABCA1
protein accompanied by a reduced level of ABCA1 mRNA [134]. These re-
cent findings and the availability of FH derived fibroblasts encouraged us to
elucidate if the lack of a functioning LDLR impact on cholesterol eﬄux and
ABCA1 regulation: thus a new pathway connecting cellular lipids uptake and
cholesterol eﬄux could contribute to intracellular cholesterol homeostasis.
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Figure 1.13: ABCA1 expression and function in LDLR_/_ macrophagesA,
LDLR_/_ reduces cholesterol eﬄux and expression of ABCA1 and ABCG1 in
macrophages. Wild type and LDLR_/_ macrophages were used to conduct free choles-
terol eﬄux. B, mRNA and protein levels of ABCA1 and ABCG1 in LDLR_/_
macrophages [133]
Chapter 2
AIM OF THE STUDY
Aim of this study was the investigation of ABCA1 transporter regulation
and function in monogenic disorders of cholesterol metabolism as Tangier
Disease (TD) and Familial Hypercholesterolemia (FH).
A first objective was the identification of new ABCA1 gene mutations in
subjects with low HDL-C levels.
A second aim was the characterization of the novel identified mutations,
preferentially employing an “ex-vivo” approach, using Tangier Disease or
FHD patients’ derived fibroblasts. If this approach was not possible due to
lack of patient derived cells, in vitro studies were performed on transfected
cells.
A third purpose of this work was the study of ABCA1 expression and
function in FH patients’ derived fibroblasts, in order to verify the existence
of a regulatory pathway connecting lipoprotein uptake and cholesterol eﬄux
in a physiological human cell model.
45
46 CHAPTER 2. AIM OF THE STUDY
Chapter 3
PATIENTS, MATERIALS
AND METHODS
3.1 Subjects analyzed between 2005 and 2009
Subjects with almost complete HDL-C deficiency (HDL-C below the 5th per-
centile of the distribution in the population: <0.77 mmol L-1 in males and
<0.93 mmol L-1 in females), suspected to have primary hypoalphalipopro-
teinemia or with clinical signs of Tangier Disease were identified by an inter-
national network of Lipid Clinics and referred to our laboratory for genetic
analysis. They were investigated in our laboratory in collaboration with the
laboratory of prof. S. Bertolini from the department of Internal Medicine,
University of Genoa.
In the last 5 years, 27 subjects with low HDL were investigated. On the
basis of biochemical (nearly absent HDL-C) and clinical data, 12 of these
patients were expected to be affected by Tangier Disease and 15 by FHD,
since they didn’t show any clinical feature except reduced HDL-C levels
(approximately half of normal value).
Informed consent was obtained from all subjects. The study protocol
was approved by the relevant institutional human investigation committees
as appropriate.
Plasma cholesterol and triglycerides were measured enzymatically and
apoA-I, apoA-II, and apoB by immunoturbidimetry (Roche Diagnostics GmbH,
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Mannheim, Germany) using an automated analyzer (Hitachi model 912, Hi-
tachi, Ltd., Tokyo). HDL-C levels were measured in plasma supernatant
after precipitation of apoB-containing lipoproteins by phosphotungstate-
MgCl2. Plasma lipoproteins were separated by density gradient ultracen-
trifugation. Two-dimensional gel electrophoresis of apoA-I was performed.
3.2 Materials
3.2.1 Buffers and media
Medium/buffer Composition
DNA loading buffer III 6X
0.25% Bromophenol Blue
0.25% Xylene cyanol
30% Glycerol
TAE 50X buffer
242 g/L Tris
57.1 ml Glacial Acetic acid
100 ml of 0.5M EDTA pH 8
LB broth
10g/L Bacto-Tryptone
5g/L Bacto-Yeast extract
10g/L NaCl taken to pH 7 with NAOH 5N
LB agar Obtained through resuspension of LB broth with
final concentration 1.5% Agar powder, then solu-
bilized via autoclavation
SOC medium
20g/L Bacto-Tryptone
5g/L Bacto-Yeast extract
0.5g/L NaCl
final 2.5mM KCl
added with final 20mM Glucose and 10mMMgCl2
P1 buffer for Miniprep 3.722 g/L EDTA, 6.055 g/L Tris, to pH 8 with
HCl plus 100 µg/ml RNAse
continued on next page
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continued from previous page
Medium/buffer Composition
P2 buffer for Miniprep
20% SDS
8 g/L NaOH
P3 buffer for Miniprep 294.45 g/L Potassium Acetate to pH 5.5 with
Glacial Acetic Acid.
TE buffer
100 mM Tris-HCl
1 mM EDTA pH 8
DMEM-F12 Glutamax-I
From Gibco
10% FBS
100 U/ml Penicillin
100 µg/ml Streptomycin
PBS 1X buffer
137 mM NaCl
2.7 mM KCl
10.1 mM Na2HPO4
1.8 mM KH2PO4
Protein extraction Buffer B
50 mM Hepes
100 mM NaCl, pH 7.4
Protein extraction Buffer C
1 mM PMSF
10 mM EDTA
10 mM EGTA
2.2% DMSO, to volume with buffer B
Lysing Buffer
1% Triton X100
0.5 mM Leupeptin, to vol. with buffer C.
Laemmli sample Buffer 1X
62.5 mM Tris-HCl pH 6.8
2% SDS
25% Glycerol
0.01% Bromophenol blue
continued on next page
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continued from previous page
Medium/buffer Composition
SDS-PAGE Resolving gel 8%
4.6 ml ddH2O
2.7 ml of 30% Acrilamide mix
2.5 ml of 1.5M Tris pH 8.8
0.1 ml of 10% SDS
0.1 ml of 10% Ammonium Persulfate
0.006 ml TEMED for a total vol. of 8 ml.
SDS-PAGE Stacking gel
2.7 ml H2O
0.67 ml of 30% Acrilamide
0.5 ml of 1M Tris pH 6.8
0.04 ml of 10% Ammonium Persulfate
0.04 ml of 10% SDS
0.004 ml of TEMED for a total vol. of 4 ml.
Western Solution 10X
30.3 gr Tris
144 gr Glycin in 1L of water
SDS-PAGE Running buffer
10% Western Solution
1% SDS
Western Blot Transfer buffer
10% Western Solution
20% Methanol
TBS 10X
0.1 M Tris pH 7.5
1M NaCl
TBS-T 1X
10% TBS 10X
0.1% Tween 20
Table 3.1: Buffers and Media
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3.2.2 Instruments and softwares
In the following table a list of all instruments and softwares used is provided:
Web-based tools and softwares
Software Type URL
PolyPhen In silico prediction http://genetics.bwh.harvard.edu/pph
Panther In silico prediction http://www.pantherdb.org/
Automated Splice Site Analysis Software In silico prediction https://splice.uwo.ca
WebCutter DNA restriction map http://rna.lundberg.gu.se/cutter2/
BLAST Basic Local Alignment
Search Tool
http://blast.ncbi.nlm.nih.gov/
The QuickChange® Primer Design Pro-
gram
Mutagenesis Primer De-
sign
http://www.stratagene.com/
Mutation Discovery PCR Protocol Writer http://www.mutationdiscovery.com/
WAVEMAKER Software DHPLC NAVIGATOR
software
-
Sequence Scanner, Applied Biosystems Sequence Analysis Soft-
ware
https://products.appliedbiosystems.com/
Instrument Type
DHPLC WAVE® DHPLC Instrument (Transgenomic Inc.)
Thermal Cycler Biometra T3 Thermalcycler, Dasit.
DNA sequencer ABI Prism®3100 genetic Analyzer.
FACS Epics XL cell sorter, Coulter.
Confocal microscope Leica DM IRE2; Leica Microsystems GmbH, Wetzlar, Germany
Table 3.2: Instruments and softwares.
3.3 Methods
3.3.1 Isolation of DNA from peripheral blood
Genomic DNA was extracted from peripheral blood leucocytes by Invisorb®
Spin Blood Maxi Kit (Invitek, GmbH, Berlin, Germany) according to man-
ufacturer’s instructions.
52 CHAPTER 3. PATIENTS, MATERIALS AND METHODS
3.3.2 Polymerase Chain Reaction (PCR)
The molecular analysis of an heterogeneous sample like DNA demands a
former selective amplification of the sequence of interest.
The general protocol for DNA amplification requires a final volume of 50
µl, containing:
• Genomic DNA (∼= 0.1 µg) 2 µl
• dNTPs (final 10 mM of each one) 1 µl
• MgCl2/MgSO4 (2 mM final) 4 µl
• Buffer (final 1X) 5 µl
• Primer (75 pm of each one) 1 µl
• Taq (2.62 U/sample) 0.7µl
• ddH2O until final volume
In our laboratory we employed two different polymerases namely:
• DNA polymerase Expand™ High Fidelity PCR System (Roche Diagnos-
tics Gmbh, Mannheim, Germany) obtained through a combination of
a heat-stable polymerase, an enzyme originally isolated from the bac-
terium Thermus aquaticus (Taq), and a Pwo DNA polymerase with
a 3’-5’ exonuclease proof-reading activity which gives a higher fidelity,
yield and specificity in DNA synthesis. This polymerase was used for
standard PCR amplification.
• Optimase Polymerase (Transgenomic, Inc., Omaha, NE, USA), with a
3’-5’ exonuclease activity was used for amplification prior to DHPLC
analysis, drastically reducing mis-incorporations during amplification
and the interference with the stationary phase of the chromatographic
column.
Two different amplification programs were used for the 50 exons of ABCA1
gene, due to the different annealing temperatures required by the primer-
couples:
Amplification program 3 steps 60°-72°C:
• 3 minutes at 95°C
• 40 seconds at 95°C
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• 40 seconds at 60°C
]
29 cycles
• 2 minutes at 72°C
Used for exons: 2Õ8, 10Õ15, 17Õ24, 26, 27, 29, 32, 33, 35, 38, 40.
Amplification program 3 steps 63°-72°C:
• 3 minutes at 95°C
• 40 seconds at 95°C
• 40 seconds at 63°C
]
29 cycles
• 2 minutes at 72°C
Used for exons: 9, 16, 25Õ28, 30, 31, 34, 36, 37, 39, 41Õ47, 49.
Three different programs have been used for exons 1, 48 and 50 under
advice of the DHPLC Company, Transgenomic (www.mutationdiscovery.
com).
Amplification program 3 steps 61.4°-72°C for Exon 1
• 2 minutes at 95°C
• 30 seconds at 95°C
• 30 seconds at 61.4°C
]
29 cycles
• 50 seconds at 72°C
• 5 minutes at 72°C
Amplification program 3 steps 58.7°-72°C for Exon 48:
• 2 minutes at 95°C
• 30 seconds at 95°C
• 30 seconds at 58.7°C
]
29 cycles
• 30 seconds at 72°C
• 5 minutes at 72°C
Amplification program 3 steps 61°-72°C for Exon 50:
• 3 minutes at 95°C
• 40 seconds at 95°C
• 40 seconds at 61°C
]
29 cycles
• 2 minutes at 72°C
3.3.3 DHPLC
The DHPLC (Denaturing High Performance Liquid Chromatography) is a
sensitive, fast and specific automated technique for a large-scale screening of
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sequence variations (both rare pathogenic mutations and common nucleotide
polymorphisms).
DHPLC appears to be a reliable method mainly for the analysis of large
genes known to be highly polymorphic and with a large variety of pathogenic
mutations. Numerous reports in the last years documented the high accu-
racy and excellent sensitivity of DHPLC (96–100%) in detecting mutations
in more than 250 genes [109]. Thus, due to ABCA1 noteworthy dimension,
it is sensible to perform a pre-screening through DHPLC that might limit
the following Sanger’s sequencing step just to a short number of positive
PCR samples. The sequencing reaction is still a necessary step for a com-
plete characterization of the identified variants, being the DHPLC only a
qualitative method [80,135].
3.3.3.1 Basic Principles
DHPLC is a technology based on the detection of heteroduplexes in PCR
products through ion-pair reversed-phase liquid chromatography under par-
tial denaturing conditions within an acetonitrile gradient. Heteroduplexes
and homoduplexes are the result of chance re-association of DNA strands
after a denaturation cycle in a heterozygous sample. In detail, denatured
and re-natured wild type PCR products lead to a homogenous population
of DNA duplexes, perfectly matched, known as homoduplexes. PCR prod-
ucts containing a heterozygosity and undergoing a cycle of denaturation and
re-naturation, will lead to four different duplex populations: two perfectly
matched homoduplexes and two mismatched heteroduplexes. The presence
of a sequence mismatch leads to a reduced column-retention time compared
with their homoduplex counterparts. The software transforms this differ-
ent elution-time in a graphic with a unique peak if the analyzed sample is
homozygote, while a multi-peak profile will refer to a heterozygous sample
(where heterozygosis may be for one or more sequence variants). With the
purpose of identifying a homozygous variation, it is required to mix the PCR
product with a WT sample in order to artificially reproduce the heterozygous
condition.
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3.3.4 Electrophoresis on Agarose gel
A control of the DNA amplification was performed through an electrophore-
sis on Agarose gel at 1-1.5%, stained with Ethidium Bromide; 5 µl of each
amplification product are mixed with 1 µl of Loading Buffer 6X and loaded
on a gel together with a molecular weight marker, in order to qualitatively
and quantitatively verify the specificity of the PCR fragment. After elec-
trophoresis it is possible to detect the amplicon as a neat, single band using
a transilluminator. If the intensity of the band was weak, it was necessary
to increase the DHPLC injection volume or the volume used for direct se-
quencing, with the aim to obtain highly comparable samples.
3.3.5 DHPLC sample preparation
Before loading in the DHPLC system, PCR products underwent a denatura-
tion and renaturation cycle by heating for 5 minutes at 95°C and gradually
decreasing temperature to room temperature; this step leads to DNA du-
plexes formation.
Afterwards, PCR products were loaded in a 96-wells platform, automat-
ically injected in the DHPLC system, analysed and eluted again after nearly
8 minutes.
The analysis report appeared as a chromatogram, where peaks were de-
tected by an UV transilluminator at a wavelength of 260 nm.
Our approach was based on the DHPLC analysis as pre-screening step of
all 50 ABCA1 amplicons; only the DHPLC positive amplicons were subjected
to direct sequencing.
3.3.6 Purification of PCR products
Before performing direct sequencing it was necessary to purify the amplifi-
cation products in order to eliminate primers, dNTPs, and genomic DNA,
which were not incorporated during the PCR reaction. On this purpose we
used the High Pure PCR Product Purification Kit (Roche Diagnostics S.p.A.
Roche Applied Science, Monza (MI), Italy
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3.3.7 Sequence reaction
In order to sequence ABCA1 gene we performed a “cycle sequencing” using
the chain-terminator method (or Sanger method). The key principle of the
Sanger method is the use of dideoxynucleotide triphosphates (ddNTPs) as
DNA chain terminators. In detail, we used the Dye-terminator sequencing,
where the four ddNTPs chain terminators are labeled with fluorescent dyes,
each of which has different wavelengths of fluorescence and emission.
The sequencing reaction is performed as follows:
• Big-Dye Terminator Ready Reaction Mix 2 µl
• Purified PCR product 5-7 µl
• Forward or Reverse Primer 1 µl
• ddH2O until a volume of 10 µl.
For each exon it was necessary to perform two different reactions, either with
a Forward primer or a Reverse primer so that it could be possible to compare
the two complementary sequences in order to have a more reliable result.
The reaction was carried out in a Biometra T3 Thermalcycler with the
following conditions: 96°C for 10 sec, 50°C for 15 sec, 60°C for 4 min for 25
cycles.
3.3.8 Purification of sequence reactions
With the aim to eliminate unused fluorochromes, a purification step was
accomplished as follows:
• Addition of 2 µl of 3M Sodium Acetate (pH 4.6) and 50 µl of Ethanol 100% to the
sequence reaction
• Incubation on ice for 10 minutes.
• Centrifugation at 13200 rpm for 30 minutes.
• Discard of the supernatant.
• Washing with 250 µl of ethanol 70%.
• Centrifugation at 13200 rpm for 5 minutes.
• Discard of the supernatant.
• Drying of the pellet for 5 minutes at room temperature.
Samples were maintained at -20°C before loading in the Genetic Analyzer (ABI
Prism®3100, Applied Biosystems, Inc, Foster City, CA, USA).
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The instrument used in our laboratory was an automatic DNA sequencer
formed by 16 capillaries. Each purified sample was resuspended in 6 µl of
ddH2O and 2 µl of this sample were loaded in a 96-wells platform with 10
µl of Formamide.
After running, the raw data were analyzed by a Sequencing Analysis
Software and an electropherogram was elaborated.
3.3.9 Screening of ABCA1 gene mutations
Our diagnostics approach allowed us, in collaboration with Prof. Bertolini’s
lab at the Department of Internal Medicine, University of Genoa, to iden-
tify 22 ABCA1 mutations. Each new mutation was screened in a control
population (50-100 alleles) mainly by DHPLC or enzymatic methods. The
mutation screening work was mainly performed by prof. Bertolini’s lab.
3.3.10 In silico prediction
We performed computational analysis of the missense mutations of
ABCA1 using Poly-Phen (http://genetics.bwh.harvard.edu/pph/), PAN-
THER (http://www.pantherdb.org/) [136]. Splice site mutations on
ABCA1 gene were analysed through the Automated Splice Site Analysis
Software (https://splice.uwo.ca/) [137].
3.3.11 Minigene construction of ABCA1 Ex19-23
To investigate the effects of the splice site mutation in the acceptor splice
site of intron 20 (c.2961 –2 A>C) we adopted first an in vitro strategy. We
constructed a wild type ABCA1 minigene from genomic DNA of a control
subject using the following primers: 5’-GGA TCC TTC TGT GGG TTC
ATT TCT GTC TTC-3 (forward primer, complementary to intron 18, which
includes a Bam HI site at its 5’ end, highlighted by underlined nucleotides)
and 5’-GCG GCC GCA GAA ATC ATT CAC AGC CAG CAA GT-3’ (re-
verse primer, complementary to intron 23, which includes a Not I site at its
5’ end, highlighted by underlined nucleotides). The amplification conditions
were the following: 95°C for 2 min, 95°C for 30 sec/60°C for 30 sec/72°C
for 6 min for 30 cycles, followed by an extension at 72°C for 5 min. This
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minigene, encompassing a genomic region spanning from the 3’ end of in-
tron 18 to the 5’ half of intron 23 (4129 bp), was cloned in the pTargeTTM
(Promega, Madison, WI, USA) expression vector and subjected to site di-
rected mutagenesis to introduce the A>C transversion in the acceptor splice
site of intron 20 (c.2961 –2 A>C).
3.3.12 Creation of the pcDNA3.1-ABCA1-GFP vector
3.3.12.1 pcDNA3.1 and pEGFP-C3
pcDNA™ 3.1(+) is a 5.4 kb vector (Invitrogen, Carlsbad, CA, USA) de-
rived from pcDNA™3 and designed for high-level stable and transient ex-
pression in mammalian hosts.
pEGFP-C3 (Clontech Laboratories, Inc., Mountain View, CA, USA)
is a 4.7 kb vector encoding for a variant of WT GFP with emission in red
and containing a Multiple Cloning Site (MCS) in 3’ position with respect
to EGFP cDNA; this means that it is suitable for cloning of proteins at the
ending of EGFP itself.
We did not use this feature but just utilized this vector as a template for
a PCR containing EGFP cDNA.
3.3.12.2 pcDNA3.1-ABCA1-GFP
A pcDNA3.1-ABCA1-GFP vector was created in our laboratory through
an overlapping PCR strategy few years ago, using as templates a pcDNA1-
ABCA1 vector (a kindly gift from Dr. Mason W. Freeman, Harvard Medical
School, Massachussets General Hospital, Boston) and the pEGFP-C3 vector
showed before.
The procedure involved:
i) Two separate PCR of the 3’ part of ABCA1 cDNA and the 5’ part of
GFP cDNA;
ii) An overlapping PCR, which allowed the fusion of the two amplicons
previously obtained [96];
iii) A subsequent cloning step by using restriction enzymes.
First the C-terminal part of ABCA1 cDNA (Ex 47-50) and the GFP
cDNA were independently amplified with specific primers (ABCA1 CtermF:
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5’-GGG CTG GAA AAT CAT CAA CTT TCA A- 3’; ABCA1 CtermR:
5’-CTT GCT CAC CAT TAC ATA GCT TTC-3’; GFP PrF: 5’-GAA AGC
TAT GTA ATG GTG AGC AAG-3’
GFP PrR: 5’-TCT TTG TCG CGG CCG CTT TAC TTG TAC AGC
TCG TCC ATG CC-3’), leading to an amplicon of 950 bp and one of 749
bp respectively.
Secondly, an overlapping PCR was conducted in order to join these two
fragments (Primers: ABCA1 CtermF: 5’-GGG CTG GAA AAT CAT CAA
CTT TCA A- 3’ and GFP PrR: 5’-TCT TTG TCG CGG CCG CTT TAC
TTG TAC AGC TCG TCC ATG CC-3’), resulting in an amplicon of 1699 bp,
containing a BamHI restriction site in ABCA1 (c.6225) and a NotI restriction
site artificially inserted in GFP cDNA.
Moreover, a specific double digestion of pcDNA1-ABCA1, pcDNA3.1
and of the overlapping PCR product was performed with BamHI and NotI
(Fermentas International Inc., Burlington, Ontario, Canada).
Among all, the following fragments were selected:
• A 6281 bp fragment containing Ex 2-47 of ABCA1 cDNA (BamHI-
BamHI cut)
• A 5378 bp pcDNA3.1 fragment (NotI-BamHI cut)
• A 1699 bp fragment obtained from the overlapping PCR and containing
the ABCA1 C-term GFP sequence (BamHI-NotI cut).
The final pcDNA3.1-ABCA1-GFP vector was achieved after purification of
the digested fragments controlled on a 1-1.5% Agarose gel; a following liga-
tion between fragments pcDNA3.1 (BamHI-NotI) and ABCA1 Cterm-GFP
(BamHI-NotI) in order to obtain a close circular plasmid with just one
BamHI-site; a digestion of this circular plasmid with BamHI, dephospho-
rylation of this one and a final ligation with the fragment ABCA1 Ex2-47
(BamHI-BamHI).
3.3.12.3 pcDNA3.1-ABCA1-GFP ∆11-33
This vector was created together with pcDNA3.1-ABCA1-GFP vector in
order to have a negative control for all the studies performed. This mutant
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Figure 3.1: Overlapping PCR strategy.
encodes an ABCA1 protein with an in-frame deletion of 1102 amino acids
(del p.K422_K1524) and, in view of its structural alteration, is expected to
be retained in the endoplasmic reticulum.
This deleted vector was obtained via digestion with the restriction en-
zyme BglII (Fermentas International Inc., Burlington, Ontario, Canada),
which has 3 restriction sites on ABCA1 cDNA in position 1265 bp, 2327 bp
and 4571 bp. The digestion of pcDNA3.1 ABCA1-GFP led therefore to 3
fragments which were isolated via purification on an Agarose gel; the two
central fragments of 1062 bp and 2244 bp were eliminated and the vector
closed up by ligation, maintaining ABCA1 sequence in frame.
3.3.13 Transformation chemically competent E.coli
Tranformation of chemically competent E.coli was performed for the au-
tonomous auto-replication of the vectors and isolation of a large amount
of plasmid DNA, necessary for the following experiments. We employed
TOP10F chemically competent E. coli (Invitrogen, Carlsbad, CA, USA) for
the transformation of pcDNA3.1 ABCA1-GFP and pcDNA3.1-ABCA1-GFP
∆11-33 while JM109 competent cells (Promega Corp., Madison, WI, USA)
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were employed for the transformation of the pTARGET vector encoding for
the minigene ABCA1 Ex19-23.
Since all vectors carried an ampicillin-resistance gene, ampicillin (50
µg/ml) was added to LB agar plates and LB broths for selection of desired
colonies.
Transformation was performed according to manufacturers’ inctructions.
3.3.14 Amplification of plasmidic cDNA in prokaryotic cells
3.3.14.1 Small scale isolation of plasmid DNA
Miniprep is a method that provides a simple and rapid isolation of plasmid
DNA from transformed bacterial cultures.
First of all it is necessary to prepare a number of 15 ml-tubes corre-
sponding to the number of colonies to test. Three ml of LB broth added
of 50 µg/ml ampicillin are aliquoted in each tube; with the help of a tip a
single colony is picked up and put inside the tube together with the tip and
cells are grown at 37°C over night at 225 rpm in a shaking incubator.
The following day bacterial cultures are processed in this way:
1. Collect 1.5 ml of each grown culture in a 2 ml-tube and centrifugation for 5 minutes
at 13200 rpm.
2. Pour off the surnatant and wash the pellet resuspending it with 1 ml of 0.15M
NaCl.
3. Centrifuge at 13200 rpm for 5 minutes and pour off the surnatant again.
4. Resuspend the bacterial pellet in 300 µl of P1 buffer (see 3.2.2), mix and vortex
until thorough resuspension.
5. Add 300 µl of P2 buffer (see 3.2.2) and mix by inverting the tube 4-6 times.
6. Incubate for 5 minutes at room-temperature in order to obtain cell lysis and DNA
denaturation (both chromosomal and plasmid DNA).
7. Add 300 µl of P3 buffer (see 3.2.2) and invert the tubes up and down 4-6 times in
order to obtain plasmid DNA renaturation.
8. Centrifuge for 15 minutes at 4°C at 13200 rpm to separate cell debris from nucleic
acids.
9. Transfer swiftly the surnatant in a new reservoir.
10. Treat each sample with 0.6 volumes of Isopropyl alcohol (˜ 540 µl).
11. Incubate at -80°C for 20 minutes.
12. Centrifuge at 4°C for 20 minutes at 13200 rpm.
13. Pour off the surnatant being careful of not touching the pellet.
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14. Wash with 1 ml of 70% ethanol and centrifuge at 4°C for 15 minutes at 13200 rpm.
15. Pour off the surnatant and air-dry the pellet.
16. Elute the plasmid DNA in 21 µl of ddH2O and store at -20°C.
The part of culture that is not processed can be stored at -20°C for long
periods after addition of Glycerol in a quantity equal to 30% of the total
volume and brief vortexing.
3.3.14.2 DNA selection via sequencing
It was possible to have a confirmation of the specificity of the plasmid DNA
obtained through Miniprep via sequencing.
A number of exonic primers designed for ABCA1 cDNA were used to
detect the presence of each mutation inserted in pcDNA3.1-ABCA1-GFP
vector. For every mutation it was used the primer that, when elongated,
covers the region containing the specific variation.
These primers altogether cover, when amplified, the whole length of
ABCA1-GFP cDNA.
11F TGTTCTCAGATGCTCGGAGGCTT
15F GATTCAACTTGGTGACCAAGAAG
1,4F TGGCACTGAGGAAGATGCTGAA
1,9F TTTGGGAACAGCAGTTGGATGGCTT
2F CTCAGTGGCTGTGATCATCAAGG
17F TTGCACCAAGTCCTACTGGTTTGG
2,4F GGATGTTGGTTTGCCATCAAG
2,8F TCCTGCAGAAACAGTAGTAGCACTG
3,1F GGCTGGAAACTTACACAGCAACAG
3,2F ATCAAGAAGATGCTGCCTGTGTGTCC
3,3F GCATGCAATCAGCTCTTTCCTGAAT
3,4F TCCCTGCCACACTGGTCATTATCA
4,1F TCTTCATCAGGCCCAGACCTGTAA
4,2F TTGGCAAGGTTGGTGAGTGGGCGATT
BGH TAGAAGGCACAGTCGAGG
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3.3.14.3 Large scale isolation of plasmid DNA
This procedure leads to a large amount of plasmid DNA, indispensable for
the following steps of this study. For this reason we used the QIAGEN®
Plasmid Maxi Kit (QIAGEN, Hilden, Germany): the protocol is based on
a modified alkaline lysis procedure, followed by binding of plasmid DNA to
QIAGEN Anion-Exchange Resin under appropriate low-salt and pH condi-
tions. RNA, proteins, dyes and low-molecular-weight impurities are removed
by a medium-salt wash. Plasmid DNA is eluted in a high-salt buffer and con-
centrated and desalted by isopropanol precipitation.
Before applying this procedure, a starter culture of 5 ml LB medium
(added of 50 µg/ml ampicillin) was inoculated with 200 µl of glycerolized
culture stored from Miniprep and incubated over night at 37°C in shaking
incubator at 225 rpm.
This culture was then diluted 1/500 into selective LB medium (500 µl
of starter culture in 250 ml of medium) and grown over night at 37°C in
shaking incubator at 225 rpm. Every following step was performed following
the manufacturer’s protocol.
The final pellet, consisting in plasmid DNA, was air-dried for 5 minutes
and re-dissolved in 300 µl of TE buffer pH 8.
It was possible to determinate the DNA concentration for each sample
measuring the absorbance at 260 nm with a spectrophotometer: at this
wavelength, 1U of Optic Density (O.D.) corresponds to a concentration of 50
µg/ml of DNA. The DNA quality is defined by the ratio between absorbance
at 260 nm and 280 nm, respectively related to absorbance peaks of nucleic
acids and proteins. Samples with a ratio ≥ 1.7 were considered acceptable.
3.3.14.4 Control of plasmid DNA through sequence reaction
All samples were analyzed via sequencing with all the primers listed above
(see 3.3.14.2) in order to ascertain that no mutation was introduced during
the whole procedure and culturing except for the ones desired. 100 ng of
plasmid DNA were sequenced using 10 pm/µl of each primer.
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3.3.15 Cells
3.3.15.1 HEK293 cell line
Human Embryonic Kidney 293 cells, also often referred to as HEK293 or less
precisely as HEK cells, are a specific cell line originally derived from human
embryonic kidney cells grown in tissue culture.
We mainly used these cells for functional studies of ABCA1 missense
mutations.
They were cultured in T75 flasks using a Dulbecco’s Modified Eagle
Medium (DMEM, Gibco, Invitrogen, Carlsbad, CA, USA) with 10% FBS,
penicillin and streptomycin (see 3.2.2) at 37°C in a humidified 5% CO2 in-
cubator.
Every 3-4 days of culture the cell monolayer was trypsinized with a so-
lution of 0.05% Trypsin in PBS and 0.02% EDTA. Cells were counted with
a Neubauer chamber and plated with a 1:7 dilution.
3.3.15.2 COS-1 cell line
COS is a cell line used to transfect cells to produce recombinant proteins for
molecular biology, biochemistry, and cell biology experiments. Two forms of
COS cell lines commonly used are COS-1 and COS-7.
The COS cell line was obtained by immortalizing a CV-1 cell line de-
rived from kidney cells of the African green monkey with a version of the
SV40 genome that can produce large T antigen but has a defect in genomic
replication.
When an expression construct with an SV40 promoter is introduced into
COS cells, the vector can be replicated substantially by the large T antigen.
The word COS is an acronym, derived from the cells being CV-1 (simian)
in Origin, and carrying the SV40 genetic material. We used COS-1 cells for
the in vitro analysis of the c.2961-2A>C mutation. They were cultured
in T75 flasks using a Dulbecco’s Modified Eagle Medium (DMEM, Gibco,
Invitrogen, Carlsbad, CA, USA) with 10% FBS, penicillin and streptomycin
(see 3.2.2) at 37°C in a humidified 5% CO2 incubator. Every 3-4 days of
culture the cell monolayer was trypsinized with a solution of 0.05% Trypsin
in PBS. Cells were counted with a Neubauer chamber and plated with a
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proper dilution. Wild type and mutant minigenes were authenticated by
sequencing before transfection into COS-1 cells. Transfection was performed
24 hours after seeding of cells in 60 mm Petri dishes.
3.3.15.3 Fibroblasts
The Cell Bank of the Department of Biomedical Sciences at the University of
Modena and Reggio Emilia was created during the last two decades by col-
lecting many different pathological and control cellular samples. It is mainly
composed of fibroblasts derived from cutaneous biopsies of healthy subjects
as well as patients affected by differential monogenic disorders. Among this
collection, monogenic disorders of cholesterol metabolism are well repre-
sented; thus we took advantage of the availability of Tangier Disease fi-
broblasts for a complete “ex-vivo” characterization of the ABCA1 mutations
responsible of the defect. Moreover a huge collection of FH fibroblasts gave
us the possibility to study the ABCA1 expression and function in these cells.
In the table 3.3 a complete list of the fibroblasts cells employed in this
work was listed:
Cells were cultured in T75 flasks in Dulbecco’s Modification of Eagle’s
Medium (DMEM) (Gibco, Invitrogen, Carlsbad, CA, USA), 100 IU/ml of
penicillin, and 50µg/ml of streptomycin, 2 mM L-glutamine, 10% FBS, and
95% air- 5% CO2. Every 4-5 days or when confluence was reached, the cell
monolayer was trypsinized with a solution of 0.05% Trypsin in PBS. Cells
were counted with a Neubauer chamber and plated with a proper dilution
(1.5-2*106/T75 flask).
3.3.15.4 Monocyte isolation from whole blood
10-15 ml of heparinised blood were diluted twice in RPMI 1640 (Gibco,
Invitrogen, Carlsbad, California); the mixture was layered on 1.077 g/ml
of Ficolle Paque (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), cen-
trifuged at 400g for 30 min. The mononuclear cell layer at the interphase
was collected, washed twice with a solution of PBS and centrifuged at 200g
for 15 min until depletion of thrombocytes. The whole blood collection and
monocyte isolation was performed at the CNR Institute of Physiology (Pisa,
66 CHAPTER 3. PATIENTS, MATERIALS AND METHODS
N° Phenotype Mutated Gene Nucleotide
change
Mutation State
TANGIER/FHD Fibroblasts
1 Tangier ABCA1 c.1759 C>T R587W Ho
2 Tangier ABCA1 c.66 +5 G>C /
c.844 C>T
-- / R282X C-He
3 Tangier ABCA1 c.3137 C>A A1046D Ho
4 Tangier ABCA1 c.4773 +1 G>A
/ c.814 -14 InsA
Del D1567_K1591 /
No effect
Ho
5 FHD ABCA1 c.389 G>A /
c.5398 A>C
R130K / N1800H He
6 Tangier ABCA1 c.1758 InsG /
c.4799 A>G
M586FsX629
H1600R
C-He
7 Tangier ABCA1 c.3295 G>T D1099Y He
FH Fibroblasts
1 FH LDLR c.1946G>A G528D Ho
2 FH LDLR c.97 C>T Q12X Ho
3 FH LDLR Del. Ex13-18 -- Ho
4 FH LDLR IVS15+1G>A Truncated in frame
Ins
Ho
5 FH LDLR c.2054 C>T P664L Ho
6 FH LDLR c.1056 C>G C331W Ho
7 FH LDLR Dupl.Ex16-17 Ho
8 FH LDLR Del. Ex13-15 /
c.1946G>A
-- /G528D C-He
9 FH LDLR Del. Ex2-12 -- He
Table 3.3: FH fibroblasts list.
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Italy) by the group headed by Prof. T. Sampietro.
3.3.16 Cells treatment
Cultured fibroblasts from healthy and affected individuals were subjected
to multiple treatments prior to further analysis in order to stimulate either
ABCA1 or LDLR expression.
ABCA1 expression is regulated by the LXR pathway, thus stimulation
of cells with i) a load of Free Cholesterol (FC), ii) oxysterols, or iii) a non-
steroidal agonist of LXR as T0901317, resulted in ABCA1 up-regulation.
On the contrary LDLR expression is favored by cholesterol depletion,
thus treatment of cells with iv) Lipoprotein Deprived Serum (LPDS), is a
condition, which maximize LDLR exposure on cell surface.
1. FC loading: the cell monolayer confluent monolayers were washed twice
with phosphate-buffered saline (PBS) and incubated with 30 µg/ml
of FC (SIGMA-Aldrich, St. Louis, MO, USA) for 48 h in DMEM
containing 1% FBS, 0,2% BSA.
2. Oxysterols: the cell monolayer was treated with the association be-
tween 9-cis-retinoic acid (5 µM) and 22-R-hydroxycholesterol (SIGMA-
Aldrich, St. Louis, MO, USA) for 18-20 hours in DMEM containing
10% FBS.
3. Non-steroidal LXR agonists: the cell monolayer was treated with T0901317
1-5 µM for 18-20 hours in DMEM containing 10% FBS.
4. LPDS: the cell monolayer was treated with DMEM supplemented with
10% LPDS (SIGMA-Aldrich, St. Louis, MO, USA).
3.3.17 Transfection with LipofecTAMINE 2000
Transfection is the process of introducing nucleic acids into eukaryotic cells
by non-viral methods. In our study we used this technique in order to pro-
duce the transcript encoded by the minigene ABCA1 Ex19-23 for the study
of c.2961-2A>C, or to produce the ABCA1-GFP WT and mutant, by ex-
ploiting the translational and transcriptional apparatus of the host cell. For
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this purpose we used Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA)
according to manufacturer’s instructions. It is a cationic liposome based
reagent able to assemble absorption-complexes with the negatively charged
plasmid DNA. An electrostatic reaction is thus created and the complexes
are able to enter plasma membranes.
If different format than 24-well are used, it is necessary to scale up and
down all the amounts, following manufacturer’s table.
3.3.18 RNA extraction from cells
RNA was extracted from COS-1 cells or fibroblasts using Eurozol (Euro-
Clone; Celbio, Milan, Italy) and reverse- transcribed to cDNA using Super-
Script III (Invitrogen, Carlsbad, CA, USA), following the manufacturer’s
instructions.
Total RNA was extracted from monocytes using RNeasy Plus Micro Kit
(Qiagen GmbH, Hilden, Germany), resuspended in 14 µL RNase-free water,
and quantified by measuring absorbance at 260 nm. Total RNA was reverse-
transcribed using QuantiTect Reverse Transcription Kit (Qiagen GmbH,
Hilden, Germany) in a final volume of 20 µL, according to manufacturer’s
instructions. RNA extraction from monocytes reverse-transcription was per-
formed at the CNR Institute of Clinical Physiology (Pisa, Italy) in the lab
of Dr. T. Sampietro.
We extracted and analyzed RNA for:
a) ex vivo study of the c.814 -14 InsA mutation (human fibroblasts);
b) in vitro study of the c.2961 -2 A>C mutation (transfected COS-1
cells);
c) ex vivo study of the c.2961 -2 A>C mutation (human monocytes);
d) ex vivo analysis of the c.4773 +1 G>A mutation (human fibroblasts).
3.3.19 ABCA1 cDNA analysis
a) To study the effect of the intronic variant c.814 -14 InsA on ABCA1 pre-
mRNA splicing, cDNA was amplified using a forward primer complementary
to exon 5 (5’ TGT TCT CAG ATG CTC GGA GGC T-3’) and a reverse
primer complementary to exon 13 (5’ TTC CAG TGA ACA CAA TAC
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CAG CC-3’). The incubation conditions were 95°C for 2 min, 95°C for 30
sec/65.1°C for 30 sec/72°C for 140 sec for 15 cycles with a reduction of 0.5°C
per cycle, followed by 95°C for 30 sec/58.1°C for 30 sec/ 72°C for 140 sec
for 20 cycles and a final extension at 72°C for 5 min. The expected size of
the wild type RT-PCR product was 1308 bp. The RT-PCR products were
separated on 1% agarose gel electrophoresis and sequenced.
b) To study the effect of the c.2961 -2 A>C mutation in vitro, following
transfection of the minigene ABCA1 Ex19-23 in COS-1 cells, RNA extrac-
tion and reverse-transcription, the following primers were used: i) 5’-AAT
GGA GCG GGG AAG ATG ACC ACC ATG TCA ATC–3’ (forward primer
complementary to exon 19/exon 20 junction); ii) 5’-GAG TAA GGG TCC
ACA CCA GC–3’ (reverse primer complementary to exon 22). The amplifi-
cation conditions were the following: 95°C for 2 min, 95°C for 30 sec/67.3°C
for 30 sec/72°C for 40 sec for 15 cycles with a reduction of 0.5°C per cycle;
95°C for 30 sec/60.3° C for 30 sec/ 72°C for 40 sec for 20 cycles, followed
by an extension at 72°C for 5 min. The RT-PCR products were separated
on 1% agarose gel electrophoresis and sequenced. The expected size of the
transcript of the wild type minigene was 398 bp.
c) To study the effect of the c.2961 -2 A>C mutation in patients’ mono-
cytes, ABCA1 cDNA of the proband and his father were amplified with the
following primers: i) 5’-GGCCTGGCACTGAATTTTTA-3’ (forward primer
complementary to exon 19); ii) 5’-AGATGATGGCAATCCTGTCC-3’ (re-
verse primer complementary to exon 23). The amplification conditions were
the following: 95°C for 2 min, 95°C for 30 sec/56,2°C for 30 sec/72°C for
60 sec for 30 cycles, 72°C for 5 min. The expected size of the PCR product
from control cDNA was 562 bp. The RT-PCR products were separated on
1% agarose gel electrophoresis and sequenced.
d) To study the effect of the mutation in the donor splice site of intron 35
(c.4773 +1 g>a) on ABCA1 pre-mRNA splicing, cDNA was amplified using
the following primers: 5’-ATC AAG AAG ATG CTG CCT GTG TGT CC-
3’ (forward primer complementary to exon 31) and 5’-TTT CAC CAT GTC
GAT GAG CCC T-3’ (reverse primer complementary to exon 40). The
amplification conditions were the following: 95°C for 2 min, 15 cycles at
95°C for 30 sec/ 67.1°C (– 0,5°C/cycle) for 30 sec/ 72°C for 110 sec, followed
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by 20 cycles at 95°C for 30 sec/ 60.1°C for 30 sec/ 72°C for 110 sec and a
final extension at 72°C for 5 min. The expected size of the PCR product
from control cDNA was 1065 bp. The PCR products were separated on 1%
agarose gel electrophoresis and sequenced.
3.3.20 Cells Staining and Confocal Microscopy
In order to perform confocal microscopy analysis of mutant ABCA1 pro-
tein sub-localization, HEK293 cells were transfected on a variable number of
Lab-tek, depending on the number of constructs contemporary transfected.
100000 cells were seeded in each well, value set up on the base of HEK293
cells’ ability to reach 40-60% of confluence the day after.
We used non-transfected cells as negative control and cells transfected
with pcDNA3.1-ABCA1-GFP as positive control for plasma membrane lo-
calization. HEK293 cells transfected with pcDNA3.1-ABCA1-GFP ∆11-33
were used as controls for Endoplasmic Reticulum retention.
3.3.20.1 Fixation of HEK293 cells
Forty-eight hours after transfection, HEK293 cells were fixed on the glass-
surface of the Lab-tek.
The steps applied are:
1. Remove medium and wash twice with 1-1.5 ml of PBS.
2. Cover the cell monolayer with 1 ml of fixing solution, consisting in 4% Paraformalde-
hyde and 2% Sucrose.
3. Incubate at room-temperature for 25 minutes.
4. Remove fixing solution and wash twice with 1-1.5 ml of PBS.
5. Cover the cell monolayer with 1-2 ml of PBS and keep in the dark at 4°C.
3.3.20.2 Labeling with anti-Calnexin antibody
With the aim to evaluate in a specific way the intracellular localization of WT
and mutant ABCA1 proteins produced by HEK293 cells after transfection,
Endoplasmic Reticulum was labeled with an anti-Calnexin antibody (Rabbit
anti-Calnexin antibody, SIGMA-Aldrich, St. Louis, MO, USA) after plasma
membrane permeabilization.
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This procedure allowed us to label the ER in order to obtain some coordi-
nates on intracellular protein localization of ABCA1. Infact calnexin (CNX)
is a 90 kDa, non-glycosylated chaperone protein, abundant in the transmem-
brane region of Endoplasmic Reticulum; it is a type I, integral membrane
protein, Calcium-binding.
Our purpose was to obtain through confocal microscopy images where
ABCA1-GFP chimera was labeled with green fluorescence (emitted by GFP),
while calnexin was labeled with a red fluorescence (achieved through the use
of a secondary antibody TRITC conjugated).
Treatment for permeabilization requires:
• Wash of the cell monolayer with 1.5 ml of PBS
• Permeabilization in ice with 1-1.5 ml of 0.1% Triton X100 for 5 minutes.
• Two-three washes of the cell monolayer with 1 ml of PBS, with 5 minutes-incubation
between the washes.
• Block of permeabilization with 1.5 ml of 1% BSA in PBS for 1 hour.
• Wash of the monolayer with 1.5 ml PBS and addition of the primary antibody
diluted 1:100 in 0.1% BSA at room-temperature for 1 hour.
• Two washes of the cell monolayer in 1.5 ml of 0.1% BSA with 5 minutes-incubation
each time.
• Addition of the Anti-Rabbit IgG (whole molecule) TRITC conjugated antibody
produced in goat diluted 1:100 in 0.1% BSA at room-temperature for 1 hour.
• Two washes with 1.5 ml of 0.1% BSA with 5 minutes-incubation each time.
• Two washes with 1.5 ml of PBS and cover of the monolayer with 2 ml of PBS.
After washing again the monolayer with PBS, images were acquired using
a Leica TCS-4D Confocal Microscope with an immersion 63X objective and
laser lines at 488 nm for GFP and 575 nm for the anti-rabbit IgG TRITC-
conjugated antibody (SIGMA-Aldrich, St. Louis, MO, USA).
3.3.21 Protein extraction from cells
Cultured skin fibroblasts were washed twice with Buffer B, scraped from
flasks in Buffer C, centrifuged at 16 100 g for 5 min and resuspended in
lysing buffer. Pellets were homogenized in a 1 mL syringe, centrifuged for 5
min at 16 100 g and supernatants were collected.
Proteins extracts were quantified through Bradford Assay, performed
in parallel with a Bovine Serum Albumine standard curve. The Bradford
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reagent was purchased from SIGMA-Aldrich (St. Louis, MO, USA); 2 µl
of proteins extracts were added to 1 mL of Bradford reagent and quantified
by reading absorbance at 595 nm. Protein extracts were either loaded on
SDS-PAGE either maintained at -20°C for a short period of time, since they
are very susceptible to degradation.
3.3.22 SDS-PAGE and Western Blot
The Western blot is an analytical technique used to detect specific pro-
teins in a given sample of tissue homogenate or extract. It uses gel elec-
trophoresis to separate native or denatured proteins by the length of the
polypeptide (denaturing conditions) or by the 3D structure of the protein
(native/non-denaturing conditions). The proteins are then transferred to a
membrane, either nitrocellulose or PVDF (Polyvinylidene Fluoride), where
they are probed and thus detected using antibodies specific to the target
protein [138,139].
SDS-PAGE (SDS polyacrylamide gel electrophoresis): Separation of pro-
teins happens in our case in denaturing conditions, thus by molecular weight.
Each of our samples obtained from protein extraction was analyzed via
SDS-PAGE using a 1.5mm-thick, 8% SDS-PAGE gel (see 3.2.2 for prepara-
tion of Resolving gel and Stacking gel). One lane was reserved for a molecular
weight marker (Bio-Rad Laboratories Inc., S.r.l., Segrate, Milano).
To preserve the integrity of ABCA1, samples were not heated prior to
loading on polyacrylamide gel. For LDLR protein detection samples were
heated and added with 2-4% of β-mercaptoethanol prior to loading on the
gel, in order to fully denaturate LDLR protein.
SDS-PAGE was carried out loading 20-40 µg of sample added of Laemmli
buffer (finale volume of 40 µl) in the cast gel and running it immediately at 15
mA and then (when samples crossed the Stacking gel) at 30 mA for around 1
hour in a Mini–P Tetra Cell (Bio-Rad Laboratories S.r.l., Segrate, Milano).
Transfer (Western Blot): In order to make the proteins accessible to an-
tibody detection, they were moved from within the gel onto a membrane
made of nitrocellulose.
The membrane was placed on top of the gel, and a stack of filter paper
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and sponge are placed on top and at the bottom of that. The entire “sand-
wich” was placed in a buffer solution (for Transfer buffer recipe see 3.2.2),
which helps transferring the proteins via electro-blotting. Protein binding is
based upon hydrophobic interactions as well as charged interactions between
the membrane and protein. We transferred our samples to a nitrocellulose
membrane in a Mini-P Tetra Cell in cold room for 2 hours at 200 mA.
Blocking: since the membrane has been chosen for its ability to bind
proteins, and since both antibodies and targets are proteins, steps must be
taken to prevent unspecific interactions with the antibody. Blocking of non-
specific binding was achieved by placing the membrane in a diluted solution
of protein, TBS containing 5% non-fat dry milk, with a minute percentage
of detergent such as Tween 20. The proteins in the diluted solution attache
to the membrane in every place where the target proteins have not attached.
Thus, when the antibody is added, it can attach only on the binding sites of
the specific target protein. This reduces background in the final product of
the Western blot, leading to clearer results, and eliminates false positives.
Incubation with primary antibody: after blocking, a diluted solution of
primary antibody (TBS-T containing 2.5% non-fat dry milk) was incubated
for 1 hour at room temperature with the membrane under gentle agitation.
For ABCA1 protein detection a rabbit polyclonal primary antibody against
human ABCA1 (Novus Biologicals, Littleton, CO, USA; 1:750) was em-
ployed; for LDLR protein detection rabbit polyclonal IgG anti-LDLR (PRO-
GEN Biotechnik Gmbh, Heidelberg, Germany; 1:2000) was employed [140].
In both cases the loading control was represented by β-actin protein lev-
els, which were detected with a mouse monoclonal anti- β-actin antibody
(SIGMA-Aldrich, St. Louis, MO, USA; 1:2500).
Incubation with secondary antibody: after rinsing the membrane with 3
washes in 1X TBS-T to remove unbound primary antibody, the membrane
was exposed to another antibody directed at the species-specific portion
of the primary antibody. A donkey anti-rabbit or a sheep anti-mouse (GE
Healthcare Bio-Sciences AB, Uppsala, Sweden; 1:5000) HRP-conjugated sec-
ondary antibodies were employed. Incubation was applied as for the primary
antibody and then 3 other washes in 1X TBS-T were performed.
Detection: the secondary antibodies we used were linked to a reporter
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enzyme known as horseradish peroxidase (HRP). HRP is used to cleave a
chemiluminescent agent and the reaction product gives luminescence in pro-
portion to the amount of protein detected. A sensitive sheet of photographic
film was placed against the membrane and exposure to the light from the
reaction created an image of the antibodies bound to the blot. This type of
detection is called Electro-Chemi-Luminescence (ECL).
On this purpose we used the SuperSignal Chemiluminescent Substrate
(Pierce), an ECL system which permits low picograms detection limits to be
achieved.
The protocol requires to:
• Mix the two substrate components at a 1:1 ratio to prepare the substrate Working
Solution.
• Incubate blot 5 minutes in SuperSignal West Substrate Working Solution.
• Drain excess reagent. Cover blot with clear plastic wrap.
• Expose blot to autoradiographic film into a hypercassette for 20 minutes.
All the autoradiographic films (Hyperfilm ECL 18x24 cm, GE Healthcare,
Uppsala, Sweden) were processed by bathe in a developing reagent for 15
seconds and then in a fixing reagent as long as the film cleared.
3.3.23 Eﬄux studies on transfected HEK293 cells
Eﬄux studies are the best way to evaluate mutant ABCA1 ability to medi-
ate cholesterol eﬄux to ApoA-I. This type of experiment was performed on
HEK293 after plating these cells in 12-well plates.
Day 1: SEEDING
Cells were plated at a confluency of 5x105 cells/well in DMEM + 10%
FBS without Penicillin-Streptomycin (P/S)
Day 2: TRANSFECTION
(following Lipofectamine 2000 protocol by Invitrogen)
Day 3: MEDIUM CHANGE
Morning: DMEMbase (480 µl/well) for 5 hours of incubation. After-
noon: DMEM + 10% FBS + double concentration of P/S (600 µl/well
to be added without removing the previous one).
Day 4: LABELING
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Wash with PBS 1X and incubate for 24 hours in DMEM + 1% FBS+
3 µCi/ml 3H-cholesterol + 2 µg/µl ACAT inhibitor (in order to inhibit
cholesterol esterification).
Day 5: CHASE/UP-REGULATION OF ABCA1
Wash with PBS 2X and incubate over night in DMEM + 0.2% BSA
(in order to equilibrate cholesterol pool) + 2 µg/µl ACAT inhibitor.
Day 6: EFFLUX
Wash with PBS 2X and incubate for 4-6 hours in either DMEM or
DMEM ± ApoAI 10 µg/ml.
EFFLUX DETERMINATION
Radioactivity in the medium and cells was determined by scintillation
counting and the fractional cholesterol eﬄux was calculated as the per-
centage of CPMmed/(CPMmed+CPMcell). For each construct, eﬄux
to ApoA-I was measured in triplicate in 3 independent experiments.
Non transfected cells were used as negative control.
3.3.24 Eﬄux studies on fibroblasts
Skin fibroblasts from TD and FH patients and healthy controls, grown and
maintained as described above, were used for the assay of ABCA1-mediated
cholesterol eﬄux.
Briefly, cell monolayers were incubated for 24 h in medium containing
[1,2-3H]-cholesterol (2 µCi/mL) and 1% fetal bovine Serum (FBS). Following
the 24 h labelling period, cells were washed and incubated overnight in media
containing 0.2% bovine serum albumin (BSA), in the presence or absence of
9-cis-retinoic acid (5 µmol/L) and 22-hydroxycholesterol (10 µmol/L). [1,2-
3H]-cholesterol-labelled monolayers were incubated for 6 h (eﬄux time) in the
presence and in the absence of human Apo A-I (25 µg/mL). Cholesterol eﬄux
was quantified by measuring the radioactivity of the incubation medium after
the removal of floating cells by centrifugation, using a time zero (To) set of
cells to calculate total [3H]-cholesterol content in the monolayer. Fractional
eﬄux was calculated as cpm [3H] in the medium ⁄ [3H] at To · 100. All the
eﬄux assays were performed in triplicate.
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3.3.25 Oxidase treatment and cholestenone measurement
To quantify the enrichment of cholesterol in plasma membrane, fibroblasts
were treated with cholesterol oxidase. Briefly, cells were labelled with 2
µCi/mL [3H]-cholesterol for 24 h in DMEM supplemented with 1% FBS.
Monolayers were then incubated for 18 h with 0.2% BSA with 5 µmol/L 9-
cis-retinoic acid and 2.5 µg/mL of 22-hydroxycholesterol. Cholesterol oxidase
(0.5 U/mL) was added, and cells were incubated for 4 h. Lipids were ex-
tracted with isopropanol, and radioactive cholesterol and cholestenone were
separated using thin-layer chromatography and quantified [141].
Chapter 4
RESULTS
SECTION A: DIAGNOSTICS
4.1 ABCA1 gene analysis
Subjects with HDL-C levels below the 5th percentile, suspected to have pri-
mary hypoalphalipoproteinemia or with clinical signs of Tangier Disease were
identified by an international network of Lipid Clinics and referred to our
laboratory for genetic analysis. In the last 5 years 27 subjects with low HDL
were investigated. On the basis of biochemical (nearly absent HDL-C) and
clinical data, 12 of these patients were affected by Tangier Disease and 15
by FHD, since they didn’t show any clinical feature except reduced HDL-C
levels (approximately half of normal value).
If the patient had clinical manifestations of TD besides extremely low
levels of HDL the genetic analysis was immediately centred on ABCA1 gene,
since we expected to find loss of function of two alleles in ABCA1 gene. If
the subject arrived to our attention with the unique diagnosis of low HDL-C
levels in the absence of any clinical manifestation we first analyzed other
candidate genes like Apo-AI and LCAT and subsequently ABCA1 gene.
Analysis of ABCA1 gene was carried out by an integrated approach DH-
PLC/direct sequencing [80], which was developed and validated five years ago
in order to speed up the analysis of an huge gene like ABCA1. This approach
consists of a pre-screening step performed with DHPLC and a subsequent
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sequencing step of the DHPLC positive amplicons. This semi-automated
approach allowed us to identify 22 ABCA1 gene mutations (about 1/5 of all
ABCA1 mutations reported so far):
• 6 identified in homozygous carriers;
• 6 identified in compound heterozygous carriers;
• 10 in heterozygous carriers.
So we were able to accomplish the genetic diagnosis to 14 patients out of 27;
in the remaining 13 subjects we have not found any mutation in ABCA1,
ApoAI or LCAT genes. From recent data it is expected a rate of 3 heterozy-
gotes for ABCA1 mutations out of 1000 individuals in the general population
[82]; consequently in the Italian population we could estimate the presence
of 120-150 Tangier patients. We have identified 12 Tangier disease patients
(9 Italian, 1 English, 1 Australian, 1 Pakistani) during this study; even if
less than expected, they represent, so far, all the Italian cases arrived to our
attention with a clinical diagnosis of Tangier disease.
4.1.1 List of the identified mutations
The list of mutations that we found in ABCA1 gene is reported below; besides
the nucleotide and amino acid substitution, we also reported whether the
mutations were in homozygous or heterozygous state (Ho: homozygous, C-
He: compound heterozygous, He: heterozygous) and the phenotype of the
carriers (TD: Tangier Disease, FHD: Familial HDL Deficiency).
These mutations were either reported or studied for the first time by our
group [80,99,142-144] with the exception of the mutations W590L, N1800H
and D1099Y [88,145,146].
Mutations listed in table 4.1 can be divided in:
• 2 nonsense mutations (R282X, R557X);
• 2 small insertions leading to frameshift and premature stop codon for-
mation (I74YFs.X76, M586Fs.629X);
• 4 splice site mutations (c.66 +5G>C, c.814-14 insA, c.2961 –2 A>C,
c.4773 + 1 G>A);
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EXON/INTRON NUCLEOTIDESUBSTITUTION
AMINOACIDIC
SUBSTITUTION STATE PHENOTYPE
IVS 2 c.66 +5G>C C-He TD
Ex 4 c.219 insT I74YFs.X76 Ho TD
Ex 5 c.389 G>A R130K He FHD
IVS 8 c.814-14 insA He/Ho FHD
Ex 9 c.844 C>T R282X C-He TD
Ex 9 c.850 G>A E284K He FHD
Ex 12 c.1445 A>G Y482C He FHD
Ex 13 c.1669 C>T R557X He FHD
Ex 14 c.1758 InsG M586Fs.629X C-He TD
Ex 14 c.1759 C>T R587W Ho/C-He TD
Ex 14 c.1769 G>T W590L He FHD
Ex 19 c.2819 C>T T940M He FHD
Ex 22 c.3137 C>A A1046D Ho TD
IVS 20 c.2961 –2 A>C Ho TD
Ex 23 c.3295 G>T D1099Y He FHD
IVS 35 c.4773 + 1 G>A Ho TD
Ex 36 c.4799 A>G H1600R C-He TD
Ex 37 c.5097 G>T W1699C C-He TD
Ex 40 c.5398 A>C N1800H He FHD
Ex 42 c.5689 C>T R1897W He FHD
Ex 42 c.5703 A>C R1901S C-He FHD
Ex 49 c.6588 G>C Q2196H He FHD
Table 4.1: List of mutations identified in TD/FHD patients.
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• 14 missense mutations (R130K, E284K, Y482C, R587W,W590L, T940M,
A1046D, D1099Y, H1600R, W1699C, N1800H, R1897W, R1901S, Q2196H)
If the 2 nonsense mutations and the 2 small insertions are certainly patho-
genetic, since they lead to a truncated ABCA1 transporter, little is known
about the biological impact of the splice site and missense mutations. One
of the purposes of this work was the investigation of the in vitro effect of the
splice site mutations and of some of the missense mutations.
SECTION B: FUNCTIONAL CHARACTERIZATION OF ABCA1
MUTANTS
4.2 Functional characterization of mutations
In order to accomplish this task we first selected a set of mutations consid-
ered eligible for further characterization. The selection was guided by the
following criteria:
• type of mutation;
• absence of any previous characterization;
• position of the mutation along the gene and position of the amino acid
in the protein;
• phylogenetic conservation of the mutated amino acid;
• in silico prediction of the effect of the mutation on the protein function;
• availability of skin fibroblasts from the patients
The table 4.2 reports, for each missense variant, the position of the sub-
stituted aminoacid on the protein and the in silico prediction output. We
used two different predictive softwares, namely Polyphen (ttp://genetics.
bw.harvard.edu/pph/) and PANTHER (ttp://www.panterdb.org/), to ob-
tain a preliminary idea of mutation effect. PoplyPhen assigns to each mu-
tation a score, based on physical and comparative considerations, which is
then translated into a classification consisting of 3 categories of damage:
“Benign”, “Possibly Damaging”, “Probably Damaging”. PANTHER database
otherwise works on the basis of the phylogenetic conservation of the mu-
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MISSENSE
MUTATION POSITION
In silico PREDICTION
POLYPHEN PREDICTION subPSEC score
R130K 1° EC loop Possibly damaging /
E284K 1° EC loop Benign /
Y482C 1° EC loop Probably damaging /
R587W 1° EC loop Probably Damaging -6.41899
W590L 1° EC loop Probably Damaging -3.04551
T940M 1° Walker A motif Probably Damaging -8.26504
A1046D IC Possibly Damaging -8.13301
D1099Y IC Probably Damaging -8.79834
H1600R 4° EC loop Probably Damaging -6.9287
W1699C IC Probably Damaging -8.90189
N1800H 6° EC loop Possibly damaging -3.6634
R1897W IC Probably Damaging -6.56875
R1901S IC Probably Damaging -4.90587
Q2196H C-terminal IC tail Benign -4.33333
Table 4.2: Position and in silico prediction of the missense mutations.
tated residue and assigns a score (called subPSEC score) to each mutation.
The probability that a given variant causes a deleterious effect on protein
function is estimated by subPSEC score, such that a subPSEC score of -3
corresponds to a Pdeleterious of 0.5; in other words the lower the subPSEC
score the higher is the probability of damage of the protein [136]. When a
subPSEC score is missing, it means that the residue is not highly conserved
in evolution.
W590L, N1800H and D1099Y were not novel mutations; the N1800H was
fully characterized and resulted to be causative since it showed a complete
lack of function of ABCA1 protein in terms of cholesterol eﬄux [147]. W590L
was never studied but there is another known ABCA1 variant affecting the
same position, the W590S, which was functionally investigated [147]. W590S
localized normally to the plasma membrane and was able to bind Apo-AI
as the wild type ABCA1, but it showed a reduced cholesterol eﬄux. We
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assumed that the W590L had a similar behaviour or even a lower impact
than the W590S on the protein function, since the multiple alignment some-
times shows a leucine residue in this position. The R587W was reported for
the first time by Lawn et al. in 1999 [57] and then by a group of our col-
laborators in 2001 [142] but the molecular diagnosis of the mutation wasn’t
followed by a functional analysis of the same. The A1046D was reported
by Wang J. et al. in 2000 [86] and it was characterized together with the
R587W by Singaraja R.et al. in 2006 [147] using a transfection approach.
Singaraja R. concluded that R587W clearly showed major biochemical de-
fects (virtually absent cholesterol eﬄux and highly reduced Apo-AI binding)
and that A1046D caused a reduced localization of ABCA1 to the plasma
membrane, a reduced Apo-AI binding and probably it influenced the fold-
ing of the protein or its phosphorylation. Since we obtained the cells of the
patients carrying these variants, we had the possibility to better understand
the biological effect of the R587W and A1046D without inducing an over-
expression of mutated proteins (as it is expected in “in vitro” transfection)
but using a more physiological “ex-vivo” approach.
The novel mutations E284K, Y482C, T940M, W1699C, R1897W were
selected for further analysis. For their characterization we used a transfection
approach because unfortunately we didn’t obtain the dermal fibroblasts of
carriers, and also because all of them, except the W1699C mutation (found
in a compound heterozygote) were found in heterozygous state. Even if this
part of the work is not the main focus of the present thesis, an overview of
the approach employed is given in section 4.4.
R130K, D1099Y and H1600R were identified only recently; we obtained
fibroblasts from the heterozygote carrier of both R130K and N1800H on the
same allele, the heterozygote carrier of D1099Y and the compound heterozy-
gote for H1600R and for a frameshift mutation (M586Fs.629X). On these cells
we could only perform eﬄux studies up to now; in the next future they could
be employed for further characterization. Finally R1901S and Q2196H were
not selected for further studies.
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4.3 Mutations affecting splice sites
Surprisingly for a large gene such as ABCA1, only few mutations affecting
splice sites have been reported so far in TD or FHD patients; among the 125
known mutations of ABCA1 gene only 9 variants affect splice sites. Four of
these were identified and studied for the first time by our group:
• the c.66 +5 G>C (IVS2+5 G>C) was studied in 2003. In patients’
fibroblasts three different species of mRNA were found: devoid of exon
2 (Ex2-/mRNA), exon 4 (Ex4-/mRNA) or both these exons (Ex2-
/Ex4- mRNA) [143].
• the c.814-14 insA (IVS8-14 insA) was identified both in heterozygote
and in homozygote state in patients with a milder phenotype. It was
also identified in 10 alleles out of 190 in the general population with low
HDL-C [81], so probably it is a relatively common variant of the popu-
lation with low HDL-C. We obtained the fibroblasts of the homozygote
carrier and studied its effect “ex vivo” (see 4.3.1).
• the c.2961 –2 A>C (IVS20-2 A>C) was recently identified in a patient
with clinical manifestations of Tangier Disease, and severely progres-
sive coronary and peripheral artery disease [148]. We had the oppor-
tunity to investigate the effect of this mutation with a combined ap-
proach, since on one hand we obtained the monocyte-derived mRNA
of the carrier and of an heterozygote relative; on the other hand we
created a minigene harbouring the mutation (see 4.3.3) [149].
• the c.4773 + 1 G>A (IVS35+1 G>A) was found in a Pakistani boy
of 7 years old with clinical signs of Tangier Disease associated with
developmental delay and mild facial dysmorphism. We obtained his
fibroblasts so that we could analyse mutation effects “ex vivo” (see
4.3.2).
A more detailed study of the splice site mutations and their effects is de-
scribed in the following paragraphs.
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4.3.1 Ex-vivo investigation of the c.814-14 insA
We described this variant in 2005 when we found it in heterozygous state in a
proband with low HDL-C [80]. Since then, we found again the same variant
in other two probands: i) in heterozygous state in a proband carrying also
the R130K and the N1800H mutations; ii) in homozygous state in a proband
carrying also the c.4773 +1 G>A. Frikke-Schmidt R. et al. reported the
same variant in 2004 which was found in 10 out of 190 alleles in not-affected
individuals, selected from the general population only for their low HDL-C
levels [81].
Figure 4.1: PCR products for c.814 -14 ins A analysis. Agarose gel electrophoresis
of ABCA1 cDNA isolated from cultured skin fibroblasts from a subject homozygous for a
variant in intron 8 (c.814 -14 ins A). RNA was isolated from cells before and after incuba-
tion with 22-hydroxycholesterol and 9-cis retinoic acid. Lane 1: ABCA1 cDNA in unstim-
ulated wild type cells; lane 2: cDNA in unstimulated cells from c.814 -14 ins A homozygous
carrier; lane 3: cDNA in wilt type cells incubated with 22-hydroxycholesterol and 9 cis-
retinoic acid; lane 4: cDNA in c.814 -14 ins A cells incubated with 22-hydroxycholesterol
and 9 cis-retinoic acid. MW= molecular weight marker. The 489 bp band represents the
transcript of the 18s subunit of human rRNA.
From these observations we thought that the IVS8 c.814-14 insA could
be a recurrent variant in the population with low HDL-C levels which might
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contribute to the phenotype of low HDL, by interfering with ABCA1 function
in some way.
This hypothesis was also supported by the in silico prediction of mu-
tation effect (Automated Splice Site Analysis https://splice.uwo.ca) which
suggested: a nearly 30 fold decrease in the strength of the canonic acceptor
site of intron 8; the abolishment of a criptic acceptor splice site placed at -12
with respect to the canonic one; the formation of a new splice acceptor site
at -13 and the possible creation of a new branchpoint.
In our cell bank we had the fibroblasts of the homozygous carrier of
both c.4773 +1 G>A and c.814-14 insA; even if it was a model complicated
by the presence of the 2 variants we tried to investigate the effects of the
IVS8 mutation. We extracted the total mRNA from fibroblasts, reverse-
transcribed it, and amplified the cDNA in the region spanning from exon 5
to exon 13 (amplicon size 1308 bp). PCR amplification from total cDNA
showed the presence in mutant fibroblasts (before and after stimulation of
ABCA1 expression with LXR agonists) of a single PCR product, whose size
was similar to that found in control fibroblasts. The relative abundance of
this transcript, after stimulation of ABCA1 expression by LXR agonists, was
super-imposable to that found in control fibroblasts. The sequence of this
transcript was identical to that of its wild type counterpart (Fig. 4.1 and
4.2).
We concluded that c.814-14 insA did not apparently alter ABCA1 splic-
ing and so we classified it as non-pathogenetic. Anyway the frequency in
the low HDL-C population, the in silico prediction and the limitations of
our model (carrier also of a highly pathogenetic mutation, which might have
masked the effect of the milder one) can not exclude a possible undetected
effect of this variant on ABCA1 function.
4.3.2 Ex-vivo investigation of the c.4773 + 1 G>A
The c.4773 +1 G>A was identified in a 7 years old Pakistani boy with clin-
ical manifestations of Tangier Disease. The in silico prediction (Automated
Splice Site Analysis https://splice.uwo.ca) suggested that the mutation
abolished the function of the donor splice site of intron 35. To confirm this
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Figure 4.2: Sequence of exon 8/exon 9 junction in ABCA1 cDNA. Sequence
of exon 8/exon 9 junction in ABCA1 cDNA in human skin fibroblasts. Panel A: ABCA1
cDNA in wild type fibroblasts. Panel B: ABCA1 cDNA in fibroblasts of a subject ho-
mozygous for the c.814 -14 ins A variant.
hypothesis we extracted total mRNA from fibroblasts of the homozygous
carrier, performed the reverse-transcription and the PCR from cDNA. The
region spanning from exon 31 to exon 40 was amplified and products were
analyzed by agarose gel electrophoresis and direct sequencing. The PCR
product from proband’s fibroblasts consisted of a single fragment of 988 bp,
as opposed to a fragment of 1065 bp observed in control fibroblasts (Fig.
4.3A). The sequence of the 988 bp fragment showed that exon 34 joined
directly to exon 36, with the complete skipping of exon 35 (Fig. 4.3B).
This abnormal mRNA is predicted to encode a mutant ABCA1 protein with
an in-frame deletion of 25 amino acids (del D1567_K1591) in the second
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extracellular loop.
This aberrant ABCA1 protein was produced in a very little amount as
demonstrated by western blotting (see 4.5.1). Moreover the little quantity
of ABCA1 produced was not able to promote any cholesterol eﬄux from
cells to ApoA-I (see 4.5.2) and we hypothesized that it could not reach the
plasma membrane of cells (see 4.5.3).
Figure 4.3: Analysis of transcripts generated by c.4773+1G>A mutation Anal-
ysis of ABCA1 mRNA in cultured skin fibroblasts of proband homozygous for the mutation
in the donor splice site of intron 35 (c.4773 + 1G>A). A, Agarose gel electrophoresis of the
PCR products encompassing the exon 31–exon 40 region of ABCA1 cDNA. Lanes 3 and 4:
PCR products obtained from a control cDNA. Lane 5: molecular weight markers. Lanes
6 and 7: PCR products obtained from the cDNA of the proband. B Partial nucleotide
sequence of the junction between exon 34 and exon 35 (in control cDNA, on the left) and
between exon 34 and exon 36 (in proband’s cDNA, on the right).
4.3.3 Analysis of the splice site mutation c.2961 –2 A>C
Recently we identified a new splice site mutation, affecting the acceptor
splice site of intron 20. The variant was found in a 37 years old man with
large, orange tonsils, hepatosplenomegaly and severely progressive coronary
and peripheral artery disease [148]. In silico mutation analysis (Automated
Splice Site Analysis https://splice.uwo.ca) predicted the inactivation of the
acceptor canonic splice site of intron 20.
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4.3.3.1 Ex vivo analysis of c.2961 -2A>C
We obtained the monocyte- derived mRNA of the proband and of the het-
erozygote proband’s father (kindly provided by Dr. Sampietro T, CNR Insti-
tute of Clinical Physiology, Pisa) [148]. We reverse transcribed total mRNA
of the proband, proband’s father and a control sample and amplified the
cDNA in the region spanning from exon 19 and exon 23. The control tran-
script gave a single PCR product of 562 bp (Fig. 4.4, lane 1). The sequence
of the wild type transcript showed that exon 20 was followed by exon 21 as
expected. The proband’s transcripts gave two amplification products, one
band of 623 bp and the other of 548 bp (Fig. MonocytesGel, lane 3); as
shown by Fig. MonocytesGel, lane 3, the longer transcript was more abun-
dant than the shorter one. The sequence of the upper band showed that
in the 623 bp transcript exon 20 was followed by the last 61 nucleotides of
intron 20, and the entire exon 21. This transcript appeared to be the re-
sult of the activation of a cryptic acceptor splice site in the 3’ end of intron
20. The product of this transcript was predicted to be a protein of 1024
amino acids containing a tail of 37 novel amino acids (M987M_FS1025X)
(ins c.2965 -61_-1). In the 548 bp transcript exon 20 was followed by exon
21, in which the first 14 nucleotides were deleted. This transcript was due
to the activation of a cryptic acceptor splice site within exon 21; its product
was predicted to be a protein of 999 amino acids containing a tail of 13 novel
amino acids (M987I_FS1000X (del c.2964_2977).
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Figure 4.4: Analysis of transcripts found in monocytes of c.2961-2 A>C
proband. Agarose gel electrophoresis of the ABCA1 transcripts obtained from amplifi-
cation of the cDNA derived from human monocytes. The ABCA1 cDNA region spanning
from exon 19 to exon 23 was amplified by PCR. Lane 1: control subject; lane 2: proband’s
father; lane 3: TD proband; lane 4: mock; MW = molecular size markers.
The PCR amplification of proband’s father sample (heterozygote for
c.2961 –2 A>C) gave two products too, of apparently the same size observed
in proband’s sample(Fig. MonocytesGel, lane 2), but of different intensity;
the most abundant product was the lower one, which, as revealed by direct se-
quencing, resulted by the co-migration of two different transcripts very close
in size (the 562 bp control transcript and the 548 bp mutant transcript).
The upper band corresponded, as demonstrated by direct sequencing, to the
ins c.2965 -61_-1 transcript already found in the proband [149].
4.3.3.2 In vitro analysis of c.2961 –2 A>C
We also created a mutated minigene in order to study mutation effects in
vitro. We amplified the whole genomic region spanning from intron 18 to
intron 23 and cloned it into pTARGET vector. The mutation was inserted
by site-directed mutagenesis and the wild type and mutant minigenes were
then transfected in COS-1 cell line. Through mRNA extraction, reverse
transcription and cDNA amplification we looked at the transcripts expressed
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by the wild type and mutant minigenes. The wild type minigene generated
a single transcript of the expected size (398 bp. Fig. 4.5, lanes 2 and 3).
The mutant minigene generated three transcripts of 459 bp, 384 bp and 255
bp, respectively (Fig. 4.5, lane 4) instead of the two expected on the basis
of the previous analysis on proband’s cDNA. The sequence of the wild type
transcript showed that exon 20 was followed by exon 21 as expected (Fig.
4.6A). The sequence of the mutant transcripts showed that: i) in the 459 bp
transcript exon 20 was followed by the last 61 nucleotides of intron 20, which,
in turn, were followed by the whole exon 21 (Fig. 4.6B) resulting from the
activation of the cryptic acceptor splice site in the 3’ end of intron 20. This
transcript corresponded to the longer transcript already found from patient’s
cDNA amplification. ii) In the 384 bp transcript exon 20 was followed by
exon 21, in which the first 14 nucleotides were deleted (Fig. 4.6C). This
transcript corresponded to the lower band already obtained from patient’s
cDNA amplification. iii) In the 255 bp transcript exon 20 was followed by
exon 22, with the complete skipping of exon 21 (Fig. 4.6D). This transcript
was predicted to encode a protein of 1003 amino acids with a tail of 16 novel
amino acids (M987M_FS1004X (del c.2964_3103) (Fig. 4.7). This shortest
transcript was not obtained during proband’s cDNA amplification and in the
gel it appeared the less abundant one.
Figure 4.8 also shows that the endogenous ABCA1 transcript (corre-
sponding to the region spanning from exon 19/exon20 junction to exon 22)
was detectable in untransfected COS-1 cells (lane 1). In agarose gel, the
band corresponding to this transcript migrates close to that of wild type hu-
man minigene transcript; we sequenced the endogenous transcript (including
the exon 20/exon 21) and found that it corresponded to the homologous of
ABCA1 gene in rhesus monkey (Genbank XM_001106713) from where COS-
1 cell line is derived (Fig. 4.8) [149].
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Figure 4.5: Analysis of transcripts generated by c.2961-2 A>C minigene.
Agarose gel electrophoresis of the transcripts of the mutant ABCA1 minigene (c.2961
–2 A>C) in COS-1 cells. RT-PCR of RNA isolated from COS-1 cells. A cDNA region
spanning from exon 19 to exon 22 was amplified by PCR. Lane 1: endogenous transcript
in non transfected cells; lanes 2 and 3: transcripts generated by wild type minigene; lane
4: transcripts generated by the mutant minigene; MW = molecular size markers.
4.4 “In vitro” functional characterization: design
and validation of the approach.
A mutation in ABCA1 gene could affect ABCA1 protein maturation and
function at multiple levels; for example, since ABCA1 is a transporter, func-
tioning mainly on the plasma membrane, its trafficking to the cell membrane
could be hampered by a mutation. With the purpose to monitor the intra-
cellular trafficking of ABCA1 protein, in all the cases in which we couldn’t
obtain patients’ cells, we designed a strategy based on the creation of a GFP
tagged plasmid. Briefly, starting from two different plasmids, one containing
ABCA1 cDNA and the other including the cDNA of GFP, we created an ex-
pression vector in which GFP cDNA was fused in frame with ABCA1 cDNA
at the 3’ end of ABCA1. This task was accomplished through: i) two inde-
pedent PCR of the 3’ part of ABCA1 cDNA and the 5’ part of GFP cDNA;
ii) an overlapping PCR, which allowed the fusion of the two amplicons pre-
viously obtained [96] and iii) a subsequent cloning step by using restriction
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Figure 4.6: Partial sequence of transcripts generated by c.2961-2 A>C mini-
gene. Nucleotide sequence of exon 20/exon 21 junction in transcripts of ABCA1 minigenes
expressed in COS-1 cells. Panel A: wild type transcript; Panels B-D: transcripts generated
by the mutant minigene in the following order: 459bp (B), 384bp (C), 255bp (D).
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Figure 4.7: Scheme of abnormal mRNA splicing. Schematic representation of the
abnormal mRNA splicing caused by the mutation in the acceptor splice site of intron 20
of ABCA1 minigene (c.2961 –2 A>C).
enzymes. This ABCA1-GFP plasmid was then subjected to site-directed
mutagenesis in order to introduce the specific mutations selected for study.
The constructs were transfected in HEK293 cells in which the intracellular
destination of ABCA1-GFP chimeric protein was followed by confocal mi-
croscopy (green fluorescence) [99]. Transfected cells were co-stained with
anti-calnexin antibody, as calnexin was taken as marker of the endoplasmic
reticulum (red fluorescence).
In order to validate this approach, we compared the intracellular lo-
calization of the wild type ABCA1-GFP protein with that of an artificial
mutant, consisting of a large deletion spanning from Ex11 and Ex33 (Del
p.K422_K1524). As demonstrated by figure 4.9, the ABCA1-GFP wild type
protein was localized at the plasma membrane as well as in the cytoplasm
in minute discrete granules, as expected. The overlay panel shows little co-
localization with calnexin, as indicated by a clear separation between red and
green fluorescence. The artificial mutant ABCA1-GFP del p.K422_K1524
was completely retained in the endoplasmic reticulum, as shown by the com-
plete overlay of ABCA1-GFP and calnexin fluorescence. For this reason the
artificial mutant was regarded as a positive control for ER retention.
Another important requirement for system validation was the functional
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Figure 4.8: Partial sequence of endogenous ABCA1 cDNA from COS-1cells.
Partial nucleotide sequence of some exons of endogenous ABCA1 cDNA from COS-1
cells. The nucleotide changes with respect to human ABCA1 cDNA are indicated by pink
columns.
assay of ABCA1-GFP chimera: cholesterol eﬄux was measured in trans-
fected HEK293 cells by the group headed by Prof. Bernini, from University
of Parma. As shown in figure 4.10 wild type ABCA1-GFP protein had a sig-
nificant eﬄux of 3H-cholesterol to Apo-AI, while the artificial mutant showed
an eﬄux to ApoA-I equal to the one observed in basal condition, that is
not an ABCA1 specific eﬄux. Thus we validated an experimental system in
which the two controls were represented on one side by the wild type ABCA1-
GFP and on the other side by the del p.K422_K1524 ABCA1-GFP. This
experimental setting was employed to characterize E284K, Y482C, T940M,
W1699C, R1897W but the complete description of results is not a purpose
of this work of thesis.
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Figure 4.9: Confocal microscopy image of transfected HEK293. Measure of
cholesterol eﬄux from HEK293 transfected with ABCA1-GFP wild type (A) and Del
p.K422_K1524 (B).
Figure 4.10: Cholesterol eﬄux from transfected HEK293. Measure of cholesterol
eﬄux from HEK293 transfected with ABCA1-GFP wild type and Del p.K422_K1524.
4.5 Ex vivo studies for R587W, A1046D and IVS35+1G>A
4.5.1 Protein extraction from fibroblasts and Western blot
for ABCA1 protein
As mentioned above, in our cell-bank we had the dermal fibroblasts of:
• a patient homozygous for R587W;
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• a compound heterozygote for IVS2 c.66 +5G>C and for R282X;
• a patient homozygous for A1046D;
• a patient homozygous for IVS35 c.4773 + 1 G>A;
• a patient heterozygous for R130K and N1800H (on the same allele);
• a patient heterozygous for D1099Y;
• a compound heterozygote for M586Fs.629X and H1600R.
We first concentrated on ABCA1 protein expression so, even if the R587W
and the A1046D were already studied with an over-expression approach in
an heterologous cell line, we wanted to know if the mutated ABCA1 proteins
were normally expressed in their physiological cell system. We stimulated
control and mutant fibroblasts with 22-OH-cholesterol and 9-cis Retinoic
Acid in order to induce LXR stimulation and consequently ABCA1 expres-
sion and extracted the total cellular proteins. Stimulation resulted in a 5-fold
increase in ABCA1 protein expression in control fibroblasts as shown in lanes
1 and 2 of fig. 4.11, (corresponding to the western blot analysis of control
and mutant proteins respectively). R587W ABCA1 protein, after stimula-
tion, was produced but its concentration was clearly lower than that seen in
control fibroblasts; we estimated that its content was about the 60% of that
observed in control cells (fig. 4.11, lane3). In stimulated fibroblasts from
the proband carrying the IVS2 c.66 +5G>C and R282X, ABCA1 was not
produced at all, as expected in view of the type of the two mutations, and
demonstrated by the lane 4 of fig. 4.11. In stimulated fibroblasts, carrying
the A1046D, the ABCA1 protein was detectable but in lower amount (about
1/5th of control cells). Finally, in fibroblasts from the proband homozygous
for c.4773 + 1 G>A, ABCA1 protein was hardly detectable (about 8% of
that found in control cells; lane 6, fig. 4.11) [99].
Fibroblasts derived from the compound heterozygote for c.66 +5G>C
and for R282X were regarded as negative control of ABCA1 expression,
since these mutations resulted in two ABCA1 null alleles [144]. As expected
these fibroblasts resulted completely devoid of ABCA1 protein expression
(fig. 4.11, lane 4).
Western blot analysis has not been performed yet on the fibroblasts car-
rier of R130K and N1800H, D1099Y and M586Fs.629X / H1600R since we
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obtained these cells only recently.
Figure 4.11: Immunoblot of ABCA1 protein from cultured skin fibroblasts.
Lanes 1 and 2: control fibroblasts before (lane 1) and after (lane 2) stimulation of ABCA1
gene expression with 22OH/cRA; lane 3: fibroblasts from a homozygous patient for
p.R578W mutation; lane 4: fibroblasts of a compound heterozygote for ABCA1 null alle-
les; lane 5: p.A1046D fibroblasts; lane 6: del p.D1567K1591 fibroblasts. ABCA1 protein
shown in lanes 3˘6 was from fibroblasts stimulated with 22OH/cRA. The per cent values
refer to the reduction in the intensity of the band with respect to the intensity of the band
of wild type ABCA1 (lane 2) in stimulated control fibroblasts.
4.5.2 Eﬄux studies
The same control and mutant fibroblasts were subjected to eﬄux assays in or-
der to verify the ability of ABCA1 protein to promote cholesterol eﬄux from
cells. These assays were performed in collaboration with the group headed by
Prof. F. Bernini at the Department of Pharmacological and Biological Sci-
ences and Applied Chemistries, at the University of Parma. The treatment
of fibroblasts with 9-cis-retinoic acid and 22-hydroxycholesterol (to induce
ABCA1 gene expression) resulted in a nine-fold increase in cholesterol eﬄux
to ApoA-I in control fibroblasts but had no effect in fibroblasts carrying the
R587W, the A1046D and the c.4773 + 1 G>A mutation (Fig. 4.12). All
three mutants resulted loss of function in terms of cholesterol eﬄux, since
they completely impair the cholesterol eﬄux to ApoA-I from cells.
Recently, cholesterol eﬄux to ApoA-I was measured also in fibroblasts
carrier of R130K and N1800H, D1099Y and M586Fs.629X / H1600R. The
22OH/9cRA stimulation resulted in a five-fold increase in cholesterol eﬄux
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Figure 4.12: Cholesterol eﬄux to Apo A−I in skin fibroblasts. 3H-cholesterol
eﬄux to Apo A-I in skin fibroblasts of TD/FHD patients under basal conditions and
following stimulation of ABCA1 gene expression with 22OH and cRA).
to ApoA-I, in control fibroblasts. Fibroblasts heterozygote for R130K and
N1800H, gave a cholesterol eﬄux approximately half of the one observed in
control cells, while fibroblasts carrier of D1099Y and carrier of M586Fs.629X
/ H1600R gave no eﬄux to ApoA-I, leading us to classify them as Tangier
Disease fibroblasts (Fig. 4.12).
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4.5.3 Quantification of membrane cholestenone content
Previous studies had shown that the expression of ABCA1 in normal skin fi-
broblasts treated with LXR-RXR agonists produces an increase in the size of
membrane free cholesterol pool, an effect not observed in cells from patients
with TD [35,150]. This amount of FC can be converted to cholestenone by
treatment with an oxidase, since being on the plasma membrane is accessible
to the enzyme.
Figure 4.13 shows that, following the ABCA1 induction by incubation
with LXR-RXR agonists, the membrane cholesterol increased 2.5-fold in con-
trol fibroblasts. In probands’ fibroblasts the increase in membrane choles-
terol varied considerably. In the A1046D and R587W cells this increase was
significant, although much lower than that seen in control cells (2.2 and
1.3 fold respectively), whilst in c.4773 +1G>A mutant cells no increase in
membrane cholesterol was observed. These results suggested that ABCA1
mutations present in patients’ fibroblasts show a different ability to drive the
cholesterol to the plasma membrane, even if the eﬄux process to Apo A-I is
reduced to approximately the same extent (Fig. 4.12). From these measure
we obtained also an indirect indication about the presence of ABCA1 on the
plasma membrane; it’s likely that in c.4773 + 1G>A cells the little amount
of ABCA1 protein expressed (see fig. 4.11 lane 6), was not able to reach the
cell surface.
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Figure 4.13: Quantification of membrane cholestenone content Enrichment of
cholesterol in fibroblast plasma membrane following stimulation of ABCA1 expression by
22OH and cRA. This figure shows the 3H-cholestenone content in plasma membrane before
(white bars) and after stimulation of ABCA1 gene expression (grey bars).
SECTION C: ABCA1 EXPRESSION AND FUNCTION IN
FH FIBROBLASTS
4.6 Study of ABCA1 protein in FH fibroblasts
Several studies in the last three decades, often reported low levels of HDL-C
levels in FH patients in association with the other plasma lipid abnormalities
typical of FH patients. The correlation between the low HDL trait and
FH has never been investigated until last year, when a study reported that
macrophages from LDLR-/- mice had a reduced expression and function of
ABCA1 transporter, suggesting a possible link between LDLR function and
ABCA1 mediated cholesterol eﬄux [133].
We took advantage of the availability of several FH fibroblasts cell lines,
collected in our Cell Bank during the last two decades, to assess whether
these cells showed a defect in ABCA1 protein expression and function. We
selected 9 fibroblasts cell lines (listed in Table 4.3 from our cell bank derived
from FH patients (seven homozygotes, one compound heterozygote and one
simple heterozygote) with an average of HDL-C levels of 32,5 ± 10,3 mg/dL;
they carried different mutations on the LDLR gene as specified in table 4.3.
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LDLR mutation State Class/Effect HDL-C
(mg/dL)
1 G528D Ho 2A 15,8
2 Q12X Ho 1 41,7
3 Del. Ex13-18 Ho 1 37,8
4 IVS15+1G>A Ho 2, 5, ? 18,6
5 P664L Ho 2B 37,8
6 C331W Ho 2B, 5 40,9
7 Dupl. Ex16-17 Ho 6 42,8
8 Del. Ex13-15 / G528D C-He 1/ 2A 24,7
9 Del. Ex2-12 He 1 --
MEAN 32,5 ± 10,3
Table 4.3: FH fibroblasts cell lines.
4.6.1 Western blot for LDLR
In order to ascertain the differential defect in LDLR protein we performed a
Western Blot for LDLR in all FH and in control fibroblasts.
We extracted total cellular proteins before (one control and one FH) and
after incubation of fibroblasts in a medium containing LPDS (LipoProtein
Deprived Serum), which is known to induce LDLR expression leading to an
increase in LDLR on the cell surface.
As expected, before LPDS treatment, LDLR was mainly present in its
immature form in control cells (Fig. 4.14 upper panel, lane 1). Treatment
with LPDS induced the appearance of the mature form of LDLR in con-
trol cells, while the precursor was not detectable anymore (Fig. 4.14 upper
panel, lane3). In G528D fibroblasts (Fig. 4.14 upper panel, lane 2) only
the precursor of LDLR was detectable in western blot, both before and after
treatment with LPDS (Fig. 4.14 upper panel, lane 2 and 4); this mutation is
classified as 2A so a complete block of receptor trafficking in the endoplasmic
reticulum was expected.
Fibroblasts carriers of the Q12X (class 1 mutation) were completely lack-
ing LDLR protein (Fig. 4.14 upper panel, lane 5). Otherwise, cells carriers
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of the Del. Ex13-18 showed the expression of an LDLR of reduced size (Fig.
4.14 upper panel, lane 6), due to the premature truncation caused by the
large deletion; probably this protein was either retained or secreted but it
was completely devoid of function.
Cells derived from the compound heterozygote, carrier of Del. Ex13-15
and G528D, showed only one band in the blot probably corresponding to
the G528D allele, so to the immature form of the receptor (Fig. 4.14 upper
panel, lane 7).
Cells carrying the Del. Ex2-12 in heterozygous state showed the expres-
sion of only the normal allele, resulting in a pattern super-imposable to the
one of control cells (Fig. 4.14 lower panel, lane 1 and 2). C331W and P664L
mutations caused the expression of the mature form of LDLR but also a
certain amount of the protein remained in the immature form as expected
since these were classified as 2A mutations (Fig. 4.14 lower panel, lane 3 and
4). Duplication of Exon16 and 17 had a migration pattern super-imposable
to the one of control cells (Fig. 4.14 lower panel, lane 5), probably because
this mutation causes a difference in size of only five amino acids [151]. Fi-
nally the splice site mutation IVS15+1G>A exhibited the presence of both
the mature and the precursor form; this mutation caused the formation of
three different mRNAs, one truncated, one with an in frame insertion and
one with an in frame deletion [152].
4.6.2 ABCA1 protein expression in FH cells
Once confirmed the defect in LDLR protein expression in all FH fibroblasts
selected, we pointed our attention to the ABCA1 transporter expression,
which was investigated by western blot. ABCA1 expression was first studied
in basal culture conditions, namely in presence of a 10% of FBS in the culture
medium. Under these conditions ABCA1 expression resulted always lower
in FH fibroblasts than in control fibroblasts (Fig. 4.15). There was a high
degree of variability in ABCA1 expression among the different FH cases, but
all of them resulted lower in intensity than controls. The presence of serum
and of its lipoproteins probably caused a differential uptake of lipoproteins
from the medium between FH and control fibroblasts, which could account
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Figure 4.14: Immunoblot of LDLR protein from cultured skin FH fibroblasts.
Upper panel; Lanes 1 and 2: control and G528D FH fibroblasts before LPDS treatment,
lanes 3˘7: control and FH fibroblasts after LPDS tratment. Lower panel: control and FH
fibroblasts after LPDS tratment.
for the observed difference in ABCA1 expression.
We then loaded control and FH fibroblasts with free cholesterol in ab-
sence of serum in the culture medium [14]. Our first issue was to verify if
control and FH cells had a similar uptake of FC from the culture medium,
so the intracellular mass of FC was measured before and after loading (Prof.
Bernini’s group, University of Parma). It was demonstrated that cholesterol
loading resulted in a significant increase in intracellular cholesterol mass,
both in control and FH cells. There was a slight reduction in the uptake of
FC in FH cells (about 10%) but was not statistically significant (Fig. 4.16).
As a control for decreased intracellular cholesterol mass was taken a Tangier
Disease fibroblasts cell line.
Cholesterol loading was reported by several studies to induce ABCA1
expression through the generation of oxysterols [14,53,153]. The western
blot analysis demonstrated that upon cholesterol loading ABCA1 protein
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Figure 4.15: Immunoblot of ABCA1 protein from cultured skin FH fibroblasts.
Basal conditions. A, B: ABCA1 protein expression in control and FH fibroblasts under
basal culture conditions (i.e. in presence of FBS 10%.
was induced both in control and FH cells but in FH it did not reach the level
found in controls (Fig. 4.17).
Figure 4.16: Measure of intracellular cholesterol mass in control, FH and
Tangier fibroblasts. Measure of intracellular cholesterol mass in control, FH and Tangier
fibroblasts before and after loading with 30 µg/ml of non-lipoprotein cholesterol.
Since ABCA1 expression is induced by the activation of the nuclear re-
ceptor LXR we treated control and FH fibroblasts with agonists of LXR
in order to up-regulate ABCA1 protein. Cells were incubated with 22-
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Figure 4.17: Immunoblot of ABCA1 protein from cultured skin FH fibroblasts.
Cholesterol loading. ABCA1 protein expression in control and FH fibroblasts upon
loading with 30 µg/ml of non-lipoprotein cholesterol.
hydroxycholesterol and 9-cis-Retinoic Acid, which acted as LXR-RXR lig-
ands [99]; after treatment, ABCA1 expression was markedly increased as
demonstrated by the western blot shown in figure 4.18. In control cells we
always obtained a strong up-regulation of ABCA1 protein expression (Fig.
4.18 A, B lane 1) while Tangier fibroblasts (with ABCA1 null alleles) were
regarded as negative controls (Fig. 4.18 A, lane 6, B lane 8). A greater vari-
ability was observed in ABCA1 expression in FH cells, but again it resulted
always lower than the one exhibited by controls (Fig. 4.18 A, lanes 2-7, B
lanes 2-5, C lanes 2-6).
Finally we incubated and four FH fibroblasts with a non-steroid agonist
as T0901317. T0901317 is known to induce an over-expression of ABCA1
gene, through its action on LXR. We obtained a great up-regulation of
ABCA1 protein, as shown by Fig. 4.19 A and B, with a similar degree
of expression in FH and control fibroblasts.
Our findings were further corroborated by the work of Mosig et al.,
published during the course of our experimental work, reporting a reduced
ABCA1 protein expression and mRNA levels in monocytes derived from
homozygous FH patients [134].
4.6.3 Eﬄux studies
In order to confirm the findings on reduced ABCA1 protein expression in
FH fibroblasts, eﬄux studies were performed in collaboration with prof.
Bernini’s group at the University of Parma. The cholesterol eﬄux from
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Figure 4.18: Immunoblot of ABCA1 protein from cultured skin FH fibrob-
lasts. LXR stimulation. ABCA1 protein expression in control and FH fibroblasts upon
stimulation of LXR pathway with 22-hydroxycholesterol and 9-cis-Retinoic Acid. A,B, C;
lane 1: control cells. A lane 6 and B lane 8: Tangier Disease fibroblasts.
FH and control fibroblasts was measured after stimulation of cells with 22-
OH-cholesterol and 9-cis-Retinoic Acid as described above (see 3.3.16). In
FH cells the eﬄux of 3H-cholesterol to ApoA-I resulted significantly reduced
in all cases, except one, with respect to control cells (Fig. 4.20).
We tried to verify if there was any linear correlation between the amount
of ABCA1 protein measured from at least three independent experiments
of Western blot (stimulation with 22OH/9cRA) and cholesterol eﬄux to
ApoAI. We found a trend towards a linear correlation (R2= 0,3), even if not
highly significant (Fig. 4.21), because of the low number of cases studied up
to now.
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Figure 4.19: Immunoblot of ABCA1 protein from cultured skin FH fibroblasts.
LXR stimulation with T0901317. ABCA1 protein expression in control and FH
fibroblasts before and after stimulation of LXR pathway with T0901317. (−) Not treated
cells; (+) Treated cells.
Figure 4.20: Cholesterol eﬄux from FH fibroblasts. Measure of 3H-cholesterol to
ApoAI after treatment of cells with 22 hydroxycholesterol and 9 cisRetinoic Acid. p-value
was calculated with T-test algortihm.
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Figure 4.21: Linear correlation ABCA1 protein - cholesterol eﬄux. Linear
correlation between the amount of ABCA1 protein in FH fibroblasts and cholesterol eﬄux,
both measured upon treatment of cells with 22OH/9cRA. The amount of ABCA1 protein
was measured with Gel-doc (Bio-Rad Laboratories Inc., S.r.l., Segrate, Milano) software
and the average value between 3 independent Western Blot experiments was calculated.
Chapter 5
DISCUSSION
SECTION A: DIAGNOSTICS
First aim of this study was the identification of ABCA1 mutations in
subjects with low plasma levels of HDL-C. We analysed ABCA1 gene with a
combined approach (DHPLC/direct sequencing) in 27 individuals. We were
able to accomplish a molecular diagnosis in 14 patients, 12 of which resulted
affected by Tangier Disease, (i.e. with complete loss of function of both
ABCA1 alleles). These patients represent all the Italian cases of Tangier
Disease, reported up to now. In the 14 carriers of ABCA1 gene mutations,
we identified 22 mutations (about 1/6 of all ABCA1 gene variants reported
so far), 19 of which are novel mutations. We performed an in silico prediction
for all missense and splice site variants in order to obtain some indications
about the biological impact of mutations.
We tried to characterize first all novel splice site mutations. To accom-
plish this goal we performed, whenever possible, an “ex-vivo” analysis, using
patients’ derived fibroblasts or monocytes; in some cases (e,g, the splice site
variant c.2961-2A>C) the study was carried out using patients’ derived cells
as well as in cells transfected with a minigene harbouring the mutation.
The c.2961-2A>C mutation resulted in the formation of two aberrant
mRNAs, detected in peripheral blood mononuclear cells derived from the
proband and his father. By contrast three aberrant mRNAs were found
in COS-1 cells transfected with a mutant minigene carrying the mutation.
While the two longer transcripts were found in patients’ cells as well as in
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transfected cells, the shortest transcript was detected only in transfected cells
over-expressing the mutant minigene. Probably this short transcript was not
produced at all in vivo or was produced in minute amounts and was rapidly
degraded. Indeed even in over-expression conditions (transfected COS-1)
this transcript was less abundant than the two longer mRNAs. This shortest
transcript was the result of the complete skipping of exon 22, while the longer
transcripts were generated by activation of two cryptic acceptor splice sites,
located close to the canonic acceptor site. These findings highlighted that the
functional assessment of intronic mutations should be performed, whenever
possible, with two parallel approaches, the ex-vivo and the in-vitro strategy,
since these approaches complement each other thus strengthening the final
result [149].
The c.4773+1G>A mutation generated an ABCA1 protein with an in-
frame deletion of 25 amino acids in the second extracellular loop. The
ABCA1-mediated cholesterol eﬄux in fibroblasts of this patient was negligi-
ble, suggesting that the abnormal ABCA1 protein is either retained in the
endoplasmic reticulum or, if it reaches the plasma membrane, is functionally
inactive. Immunoblot analysis showed that in patient’s fibroblasts the level
of mutant ABCA1 protein was extremely low compared with the level found
in control fibroblasts. This finding indicates that this structurally abnormal
protein is probably degraded in the endoplasmic reticulum and does not reach
the plasma membrane. Indirect evidence, suggesting that the mutant protein
does not reach the plasma membrane, is given by the quantification of mem-
brane cholesterol content, which indicates that the enrichment of cholesterol
in the plasma membrane, was absent in fibroblasts of this proband. Even if
the mutant protein reaches the plasma membrane, it is probably incapable
of binding to Apo A-I, as the 25 amino acid deletion (del D1567–K1591) in-
volves the second large extracellular loop of ABCA1 (1371–1650 amino acid
residues), thought to be one of the Apo A-I binding sites. Previous studies
have shown that two missense ABCA1 mutants (C1477R and S1506L) lo-
cated in the second extracellular loop, when expressed in transfected cells,
exhibited a dramatic reduction in the interaction capacity with Apo A-I [30].
It is also possible that the 25 amino acid deletion could generate structural
changes which prevent the oligomerization of the ABCA1 protein [41,42,99].
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SECTION B: FUNCTIONAL CHARACTERIZATION OF ABCA1
MUTANTS
We also fully or partially characterized also the missense mutations:
R587W, A1046D, D1099Y, H1600R, R130K/N1800H. The R587W muta-
tion was first reported by Lawn et al. [57] in a compound heterozygote
with HDL deficiency, in whom the second allele failed to produce detectable
mRNA. Subsequently, we reported a patient with severe HDL deficiency
and premature CAD homozygous for this mutation [142], which abolished
ABCA1-mediated cholesterol eﬄux in cultured fibroblasts. Previous in vitro
experiments in transfected cells expressing the R587W mutant (designed to
define the alteration in the ABCA1 pathway) were somewhat inconsistent.
Fitzgerald et al. [30] showed that the R587W mutant reached the cell sur-
face just like its wild type counterpart, but showed a 50% reduction in the
cross-linking efficiency to Apo A-I. Singaraja et al. [147] showed that the
R587W mutation prevents the migration of the protein to the plasma mem-
brane, causing a 75% decrease in ABCA1-mediated cholesterol eﬄux. In
our patient homozygous for the R587W mutation the ABCA1 protein con-
tent was lower than that observed in control fibroblasts (Fig. 4.11 lane 3),
possibly suggesting an increased rate of intracellular degradation (an event
expected if the mutant protein is retained, at least in part, in the endoplasmic
reticulum). The reduced ABCA1 protein content in these cells is consistent
with the strong reduced ability of promoting cholesterol eﬄux and plasma
membrane cholesterol enrichment [99].
The ABCA1 A1046D was previously reported by Wang et al. [86] in a
kindred with HDL deficiency, which included three compound heterozygotes
and two heterozygotes for this mutation. Previous in vitro experiments have
shown that the A1046D mutation, which occurs in the intracellular domain
between the first Walker A and B motifs, severely impairs cholesterol eﬄux
from transfected cells, even if it does not abolish the localization of ABCA1
in the plasma membrane, where it retains a residual capacity to bind Apo
A-I [147]. Because ABCA1-mediated cholesterol eﬄux was completely abol-
ished in the proband’s fibroblasts (Fig. 4.12) we assumed that, even if this
mutant maintains a residual capacity to reach the cell surface and to bind
Apo A-I (as shown in transfected cells), it has an impaired transfer activity.
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This consideration is also consistent with the observed defect in cholesterol
enrichment in plasma membrane (Fig. 4.13). Immunoblot analysis showed
that the content of mutant ABCA1 was greatly reduced in the proband’s fi-
broblasts (Fig. 4.11 lane 5), strongly suggesting that the amino acid change
causes an increased intracellular degradation of the ABCA1 protein [99].
In conclusion previous in vitro experiments were somewhat inconsis-
tent [86,147] about mutant proteins expression since they were performed
in transfected cells, forced to over-express the mutant protein; otherwise in
our patients’ cells the observed ABCA1 protein content was always lower
than that of control fibroblasts possibly suggesting an increased rate of in-
tracellular degradation (an event expected if the mutant protein is retained,
at least in part, in the endoplasmic reticulum).
The D1099Y was found in an heterozygous patient with strongly reduced
HDL-C levels and clinical manifestations of TD. Even if we expected to find
a complete loss of function of both ABCA1 alleles, we were able to identify
only this variant in heterozygous state. We demonstrated that in fibroblasts
derived from D1099Y carrier, cholesterol eﬄux to ApoA-I was completely
absent, thus confirming our assumption that the proband was a “Tangier
Disease like” individual. We could not exclude the presence of an additional
mutation in introns, outside the coding regions or the exon-intron bound-
aries usually analysed with direct sequencing; we could not also exclude the
presence of a huge molecular rearrangement on the apparently normal allele,
which might be responsible for the obliteration of the second allele. Anyway,
since in our hands, this proband appears as a simple ABCA1 heterozygote
we hypothesized a dominant negative effect of this variant. The D1099Y
mutation was previously reported by Ho Hong et al. in 2002 [146] in a com-
pound heterozygote. This mutation occurs in a highly conserved hydropho-
bic linker region between the sixth and the seventh helix (34 aa downstream
the Walker B motif) of each transmembrane domain of ABCA1 protein,
suggesting that it may impair the specificity of the transported molecules,
ABCA1 protein oligomerization [42], or the ATP hydrolysis cycle. Indeed
the only other dominant negative mutant, reported so far in ABCA1, was
the M1091T variant [85,147], which is quite close to the 1099 residue. So we
assumed that this region of ABCA1 protein is involved in oligomerization,
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thus a single mutant allele could interfere with the normal allele by impair-
ing the assembly of multimeric protein complexes, important for the proper
transporter functioning.
We demonstrated also that fibroblasts carrier of H1600R and M586Fs.629X
showed a null cholesterol eﬄux to ApoA-I, as expected by the severe pheno-
type of the patient, and that fibroblasts heterozygous for both R130K/N1800H
showed a capacity to promote cholesterol eﬄux intermediate between con-
trol and TD cells. The latter finding was expected, since the proband was
carrier of both mutation in heterozygous state on the same allele and had
HDL values typical of an FHD subject.
The investigation of other novel missense mutations of ABCA1 gene, for
which cells of the carriers were not available, was performed using an in
vitro approach. Even if beyond the purposes of this work, we provided a
rational for the strategy used and a formal demonstration of the effective-
ness of our model. Indeed we constructed a plasmid carrying ABCA1 cDNA
fused in frame with GFP cDNA at the 3’ terminus. This vector was trans-
fected in HEK293 cells, ABCA1-GFP distribution in transfected cells was
assayed with confocal microscopy and cholesterol eﬄux was measured. As a
negative control we created an artificial ABCA1 mutant, carrier of a large
in-frame deletion, thus coding for a half transporter fused in frame with the
GFP cDNA. In transfected HEK293 cells we demonstrated that wild type
ABCA1 was mainly localized on the PM and in minute intracellular deposits
inside the ER, while the mutant ABCA1 was completely retained in the ER.
Moreover the wild type protein was able to promote a significant cholesterol
eﬄux from transfected cells, while the mutant one did not. On the basis of
these results we inserted in ABCA1-GFP cDNA the desired missense muta-
tions and studied them with this validated approach.
SECTION C: ABCA1 EXPRESSION AND FUNCTION IN
FH FIBROBLASTS
Finally we studied ABCA1 protein regulation in fibroblasts derived from
FH patients. Our purpose was to try to assess a link between the two path-
ways of cholesterol influx and eﬄux from cells. The rationale for this study
was based on two observations: i) the low levels of HDL-C often reported
in FH patients; ii) the down regulation of ABCA1 protein and mRNA in
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murine macrophages derived from LDLR -/- mice as the result of a persis-
tent activation of SREBP1 transcription factor [133]. We demonstrated the
decreased ABCA1 protein content in FH fibroblasts with respect to control
fibroblasts incubated under different conditions: i) basal culture conditions:
ii) following an ABCA1 transcriptional stimulation (22OH/9cRA), and iii) in
presence of a non-lipoprotein derived cholesterol loading. The only stimulus,
which in FH cells restored a level of ABCA1 expression similar to that found
in control cells was represented by T0901317, a non-steroidal agonist of LXR.
However this latter finding should be taken with caution, since the observed
effect is most likely due to the over-expression of ABCA1 gene induced by
the high dose of T0901317 used in the experiment.
The reduced ABCA1 protein level of FH fibroblasts was confirmed also by
cholesterol eﬄux assays, (performed with the transcriptional stimulation of
22OH/9CRA) which showed that in seven out of eight FH cell lines ABCA1-
mediated eﬄux was greatly reduced.
As suggested Zhou et al. we put forward the hypothesis that the altered
ABCA1 regulation in FH cells was consequent to an impaired intracellular
cholesterol homeostasis. Oxysterols are generated during cholesterol synthe-
sis or when intracellular cholesterol levels rise. Zhou et al. demonstrated
that in murine macrophages the response to oxysterols is different in cells
lacking the LDLR. We demonstrated that in FH fibroblasts, oxysterols were
produced because if we loaded cells with FC, ABCA1 protein is upregulated,
but the extent of the upregulation is lower than in control cells. Thus we
concluded that the oxysterols generated by FH fibroblasts were not able to
completely shut down SREBPs transcription factors; a persistent activation
of SREBPs proteins could act in the nucleus as a brake on LXR activation
and so on ABCA1 expression. SREBPs transcription factors show an inverse
pattern of expression with ABCA1 protein and the activation of the LXRE
present in ABCA1 promoter was indirectly impaired by activated nuclear
SREBP [133].
We assumed that this different behaviour between control and FH cells
could be a consequence of an impaired accessibility of oxysterols to LXR and
SREBPs or of free cholesterol to ABCA1. The distribution of intracellular
sterols depends upon the cholesterol regulatory pool; while in control cells
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the majority of cholesterol derives from lipoprotein uptake, in FH cells it
derives from intracellular cholesterol synthesis. The LDL-derived cholesterol
and the newly synthesized cholesterol belong to two different pools, which
probably have different intracellular destinations and regulations. Further
studies will be required to clarify this issue; we certainly demonstrated the
existence of a connection between lipoprotein uptake and cholesterol eﬄux,
and we provided a possible explanation for the low HDL-C levels found in
FH patients, giving further elements to consider for the treatment of these
patients.
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Appendix A
Database of mutations
identified in ABCA1 gene
Exon/
Intron
Position
and nt
change
Effect on
mRNA or
DNA
Effect on protein Phenotype State
IVS 2 c.66 +5 G>C Skipping Ex 2,
Ex 4
T Che
4 c.219 ins T I74YFs>Term76 T Ho
4 c.254 C/T CCG>CTG Pro85>Leu FHD He
5 c.389 G>A AGA>AAA Arg130>Lys FHD He
6 c.479 del A His160Fs>Term173 FHD Che
7 c.593 C/A TCA>TAA Ser198>Term FHD He
7 c.688 C/T CGT>TGT Arg230>Cys FHD He
IVS7 c.720 +6
C>T
Skipping Ex 7 Del Val 182_Leu 240 T Che
8 c.742 C/A CCC>ACC Pro248>Thr FHD He
8 c.763 G/A GCC>ACC Ala255>Thr T,FHD Ho
9 Del 8bp
(c.815-822)
(TGTTCAGC) Fs>5aa>Term276 T Che
9 c.844 C/T CGA>TGA Arg282>Term T Che
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9 c.850 G/A GAG>AAG Glu284>Lys FHD He
9 c.917 G/A CGT>CAT Arg306>His FHD He
9/IVS 9 c.1052-54
+1,2 dupl
CAAgt dupl Thr351Fs>Term360 T Ho
10 c.1091 C/G TCT>TGT Ser364>Cys FHD(pol) He
11 c.1196 T/C GTG>GCG Val399>Ala T Che
11 c.1201 A/C AAG>CAG Lys401>Gln FHD He
12 c.1375 A/C ACA>CCA Thr479>Pro FHD He
12 c.1445 A/G TAC>TGC Tyr482>Cys FHD Che
12 c.1486 C/T CGG>TGG Arg496>Trp Iperα He
IVS12-
IVS14
Del 1221nts Del Ex 13, 14 Del Ex 13, 14 T Che
13 Del 14bp
(c1584-1597);
ins 110bp
Del 6aa; ins 38aa T Ho
13 c.1651 C/G CAT>GAT His551>Asp FHD He
13 c.1664 A/C AAG>ACG Lys555>Thr Iperα He
13 c.1669 C/T CGA>TGA Arg557>Term FHD He
14 c.1719 C/A TAC>TAA Tyr573>Term T Ho
14 c.1758 ins G Met586>Fs>Term629 T Che
14 c.1759 C/T CGG>TGG Arg587>Trp T Ho,Che
14 c.1769 G/C TGG>TCG Trp590>Ser T Che
14 c.1769 G/T TGG>TTG Trp590>Leu FHD He
14 c.1790 A/G CAG>CGG Gln597>Arg T Ho
14 Del G c.1824 CT(G) 608 Fs>27aa>Term635 T Ho
14 c.1847 G/T GGT>GTT Gly616>Val FHD He
14 c.1881 C/G TAC>TAG Tyr627>Term T Che
15 c.1913 G/A CGG>CAG Arg638>Gln FHD He
15 c.1974 A/G ATC>GTC Ile659>Val FHD He
15 Del 3bp
c.2077-2079
(CTT) 693 Del Leu693 FHD He
137
16 c.2320 A/T ACA>TCA Thr774>Ser FHD He
16 c.2327 G>C AAG>AAC Lys776>Asn FHD(pol) He
IVS16-
IVS31
Del 19.9kb Del Ex 17-31 Del Ex 17-31 T Che
17 c.2444 A/G GAG>GGG Glu815>Gly FHD He
17 c.2518 T/A TGG>AGG Trp840>Arg FHD He
18 c.2602 G/A GAG>AAG Glu868>Lys FHD He
19 Del C c.2725 (C)GA Fs>3aa>Term912 T Che
19 c.2725 C/T CGA>TGA Arg909>Term FHD,T He, Ho
19 c.2737 A/T AAG>TAG Lys913>Term T Ho
19 c.2786 C/T ACC>ATC Thr929>Ile T Che
19 c.2803 A/C AAT>CAT Asn935>His T Ho,
Che
19 c.2804 A/G AAT>AGT Asn935>Ser T Ho
19 c.2810 C/T GCG>GTG Ala937>Val T Che
20 c.2893 C/T CGC>TGC Arg965>Cys FHD He
IVS20 c.2961 -2
A>C
T Ho
21 c.3077 T/C CTG>CCG Leu1026>Pro FHD He
22 c.3137 C/A GCC>GAC Ala1046>Asp T Che,Ho
22 c.3193 C/T CCT>TCT Pro1065>Ser FHD He
22 c.3202 C/T CGC>TGC Arg1068>Cys FHD He
22 c.3203 G>A CGC>CAC Arg1068>His T Ho
23 c.3272 T/C ATG>ACG Met1091>Thr FHD He
23 c.3295 G/T GAC>TAC Asp1099>Tyr FHD Che,He
23 Ins G c.3286 After codon 1095 Fs>50aa>Term1146 T Che
23 Del 2bp
(c.3340-3341)
(TC)C 1114 Fs>30aa>Term1145 T Ho
25 c.3542 C/T TCT>TTT Ser1181>Phe FHD He
25 c.3647 G/T GGA>GTA Gly1216>Val FHD He
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IVS 25 c.3738 +1
G>C
T Che
27 c.3808 C>T CGA>TGA Arg1270>Term TD Ho
27 c.3835 C>A CAG>AAG Gln1279>Lys FHD He
27 Del CGCC
c.3847-50
(CGC C)CG Fs>14aa>Term1297 FHD Ho
27 c.3865 G/A GAT>AAT Asp1289>Asn T Ho,
Che
28 c.3966 G/A TGG>TGA Trp1322>Term FHD He
28 c.4022 G/C AGA>ACA Arg1341>Thr FHD He
29 c.4126 A/G AGC>GGC Ser1376>Gly FHD He
29 c.4135 C/T CTT>TTT Leu1379>Phe T Che
29 c.4156 G/C GAA>CAA Glu1386>Gln FHD He
30 c.4261 G/T GGA>TGA Gly1421>Term FHD He
31 c.4429 T/C TGT>CGT Cys1477>Arg T Che
31 c.4430 TGT>TTT Cys1477>Phe FHD He
IVS31 c.4465 -1
G>C
Skipping Ex 32 Gln1488>Fs> Term1497 T Che
32 c.4517 C/T TCG>TTG Ser1506>Leu T Che
34 c.4595 A>G TAT>TGT Tyr1532>Cys T Che
34 Ins A c.4630 After codon 1543 Fs>8aa>Term1552 T Che
IVS35 c.4773 +1
G>A
Del Asp1567_Lys1591 T Ho
36 c.4799 A>G CAT>CGT His1600>Arg T Che
36 c.4831 A/G AAT>GAT Asn1611>Asp FHD Ho
36 c.4844 G/A CGG>CAG Arg1615>Gln FHD He
36 c.4844 G>C CGG>CCG Arg1615>Pro FHD He
36 Del GG
c.4882-3, ins
C
After codon 1627 Fs>8aa>Term1636 T Che
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37 c.4978 T>C TGT>CGT Cys1660>Arg T Ho
37 c.5008 G/A GCC>ACC Ala1670>Thr FHD He
37 c.5038 C/T CGG>TGG Arg1680>Trp T Ho
37 c.5039 G/A CGG>CAG Arg1680>Gln Iperα He
37 c.5097 G/T TGG>TGT Trp1699>Cys T Che
37 c.5111 T/A GTC>GAC Val1704>Asp T Che
37 c.5116 G/A GAT>AAT Asp1706>Asn FHD He
38 Ins 138nt af-
ter c.5122
In codon 1708 + 46aa T Che
38 c.5192 C/G TCC>TGC Ser1731>Cys FHD He
40 c.5398 A/C AAT>CAT Asn1800>His T Ho,
Che,
He
40 Del 3’
Ex40→Ex50
Del 427 terminal aa T Ho
41 c.5520 del T Codon 1640 Fs1840>Term1869 FHD He
41 c.5551 C/T CGA>TGA Arg1851>Term T Ho
41 c.5552 G/A CGA>CAA Arg1851>Gln T Che
42 Del 6bp
(c.5677-5682)
(GAAGAT) Del Glu1893, Asp1894 FHD He
42 c.5689 T/C CGG>TGG Arg1897>Trp FHD He
42 C,5703 A/C AGA>AGC Arg1901>Ser FHD Che
42 Ins 14nt after
c.5757
After codon 1919 Fs>44aa>Term1964 T Che
43 c.5774 G>A CGG>CAG Arg1925>Gln Scott Syn-
drome
He
45 c.6010 G>A AGA>AAA Arg2004>Lys FHD He
45 c.6026 T/C TTC>TCC Phe2009>Ser FHD Che,He
46 c.6082 C/T GCG>GTG Ala2028>Val FHD He
IVS 46 c.6205 -
39. . . .-46 del
T
Skipping Ex 47,
Term2073
T Che
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47 c.6217 A/G ACA>GCA Thr2073>Ala FHD He
47 c.6241 C/T CGG>TGG Arg2081>Trp T Che
49 Del C c.6430 Codon 2144
(C)GA
Fs>1aa>Term2145 T ?
49 c.6430 C/T CGA>TGA Arg2144>Term FHD He
49 c.6449 C/T CCG>CTG Pro2150>Leu FHD He
49 c.6488 T/C TTT>TCT Phe2163>Ser T Che
49 c.6532 T/C TAC>CAC Tyr2178>His FHD He
49 Del TT
c.6546-6547
TC(T T)CA Fs>20aa>Term2203 T ?
49 Ins 4bp after
c.6573
Ins CATT Fs>8aa>Term2200 T Che
49 c.6588 G/C CAG>CAC Gln2196>His FHD He
49 Del c.6601-3
ins
Del CTC ins TT Fs>2aa>Term2203 T Ho
49 c.6616 T>G TAC>GAC Tyr2206>Asp FHD He
49 c.6630 G/C CAG>CAC Gln2210>His T Che,
He
50 c.6729 C/G GAC>GAG Asp2243>Glu FHD He
50 c.6730 G/A GTT>ATT Val2244>Ile T Che
Appendix B
Database of polymorphisms
identified in ABCA1 gene
Promoter -878 C/T (-564) ↑ Aci I
Promoter -820 A/C (-506)
Promoter -721 G/C (-407)
Promoter -592 G/C (-278) ↓ Hga I
Promoter -328 C/T (-14) ↓ Bsm AI
Exon 2 -76 GGG/GG (237) ↓ Bsl I
Exon 2 -18 C/G (297)
Exon 6 474 G/A CTG>CTA Leu158
Exon 7 656 G/A AGG>AAG Arg219>Lys
Exon 8 765 C/T GCC>GCT Ala255
Exon 9 936 C/T CCC>CCT Pro312
Exon 9 948 G/A GGG>GGA Gly316
Exon 11 1196 T/C GTG>GCG Val399>Ala
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Exon 15 2040 C/A ATC>ATA Ile680
Exon 16 2311 G/A GTG>ATG Val771>Met
Exon 16 2320 A/C ACA>CCA Thr774>Pro
Exon 16 2328 G/C AAG>AAC Lys776>Asn
Exon 17 2473 G/A GTC>ATC Val825>Ile
Exon 18 2649 A/G ATA>ATG Ile883>Met
Exon 20 2880 G/A CTG>CTA Leu960
Exon 22 3159 T/G GTT>GTG Val1053
Exon 24 3516 G/C GAG>GAC Glu1172>Asp
Exon 31 4281 G/A ACG>ACA Thr1427
Exon 34 4664 C/T ACC>>ATC Thr1555>Ile
Exon 35 4760 G/A AGA>AAA Arg1587>Lys
Exon 36 4943 C/T CCG>CTG Pro1648>Leu
Exon 38 5192 C/G TCC>TGC Ser1731>Cys
Exon 44 5921 G/A AGA>AAA Arg1974>Lys
Exon 49 6447 C/T AAC>AAT Asn2149
Exon 49 6503 C/T CCA>CTA Pro2168>Leu
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e amiche che vorrei ringraziare, tra questi ricordo solamente Chiara G. che
ormai è parte della mia famiglia e che è sempre fonte di ammirazione per me
per le sue idee, la sua intraprendenza e per l’amicizia che condividiamo.
La mia famiglia più che ringraziata va abbracciata tutta intera per ri-
affermare quanto sono loro grata per l’affetto e il sostegno che continuano
a prestarmi. Prima di tutto ringrazio la mia mamma e il mio papà, che
nel frattempo sono diventati nonni, che non si scordano mai di me e sono
sempre vigili sulla mia felicità e la mia realizzazione personale; i miei cognati
Lorenzo e Serena, amici, compagni di avventure, consiglieri fidati, zii pre-
murosi. Infine un grazie a Carla che ha reso possibile gran parte di questo
lavoro, prendendosi cura nel migliore dei modi della sua "nipotina acquisita"
Anna.
I più importanti li nomino qui in fondo: Alain mio compagno di vita, per
l’amore che mi dona ogni giorno in ogni gesto che compie e in ogni parola
che mi dice e Anna per essere arrivata a “scombussolarci” e a riempirci di
gioia e di vita.
